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Abstract 
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous 
system (CNS) which has a complex aetiology that involves the interplay of both genetic and 
environmental factors. Although more than 200 susceptibility loci have been identified 
through genome-wide association studies, our understanding of the molecular mechanisms 
underlying these associations remains limited. My predecessor in the laboratory established 
that the MS associated variants rs9282641 and rs4810485 respectively influence the 
expression of CD86 and CD40 in freshly collected (ex-vivo) B cells. In my research, I sought 
to extend this work by investigating the impact of these variants in the context of activation in 
an effort to refine understanding of the molecular mechanisms underlying the effects of these 
genotypes on the risk of developing MS. 
In the first phase of my work I processed venous blood samples from 108 healthy volunteers, 
who were recruited from the Cambridge BioResource (CBR) to enable a balanced 
representation of each possible genotype. I isolated peripheral blood mononuclear cells 
(PBMCs) from these samples and then activated these with CD40L-transfected L cells. In 
line with the ex vivo results, I found that the expression of CD86 and CD40 remained 
associated with the genotypes of the respective MS associated variants. I then went on to 
investigate the effects of these stimulated cells on co-cultured naïve T cells by studying a 
second cohort of 28 volunteers recruited in pairs from the CBR; the individuals in each pair 
carrying either the AA or the GG genotype at rs9282641. In these experiments I co-cultured 
naïve T cells with purified B cells that had been activated with CD40L-transfected L cells. In 
these 12-day co-cultures, the T cells from subjects homozygous for the risk allele (GG) at 
rs9282641 demonstrated significantly enhanced proliferation and displayed significantly 
higher IFN-γ and IL-17 production, and lower IL-10 production. 
In my PhD I have therefore shown that the altered expression of co-stimulatory molecules on 
B cells induced by MS risk variants results in enhanced proliferation of pro-inflammatory T 
cells. 
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Chapter 1 Introduction 
1.1 Clinical features of Multiple sclerosis 
1.1.1 Overview and classification  
Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disorder of the central 
nervous system (CNS), which results in multiple inflammatory lesions that are disseminated 
throughout the CNS in both time and space that cause a wide range of focal neurological 
symptoms and signs (Compston and Coles, 2008; Thompson et al., 2018b). It most 
commonly affects individuals during their early adult life, and frequently results in quality of 
life being severely compromised (Cree et al., 2016; Sanai et al., 2016) and shortened (Scalfari 
et al., 2013; Lunde et al., 2017). The disease runs a highly variable course in which it 
frequently affects mobility, sensation and cognition. Ultimately significant irreversible 
disability develops in approximately 80% of MS patients (Scalfari et al., 2011; Lublin et al., 
2014). 
The early disease course in MS is broadly classified into two major categories; primary 
progressive MS (PPMS) and the relapsing-remitting MS (RRMS) (Compston and Coles, 
2008). The former, which accounts for 10-15% of cases, is characterized by the gradual 
accumulation of irreversible neurological disability, whereas the latter (85-90% of cases) is 
characterized by intermittent periods of relapses and remission; although the recovery from 
relapses often incomplete (Miller and Leary, 2007). Notably, in about 70% of RRMS patients 
relapse eventually give way to a phase of accumulating irreversible disability, or so called 
secondary progressive MS (SPMS) (Jokubaitis et al., 2016; Lorscheider et al., 2016). People 
with incidental magnetic resonance imaging (MRI) findings suggestive of MS but no clinical 
signs or symptoms, which is termed radiologically isolated syndrome (RIS), are at higher risk 
for developing into MS in the future, with one-third of patients diagnosed within 5 years 
(Okuda et al., 2014; Labiano-Fontcuberta and Benito-León, 2016). Therefore, appropriate 
follow-ups are necessary for the RIS population (Kantarci et al., 2016). From clinical and 
statistical perspectives, MS natural history data suggests that the condition is best regarded as 
one disease with a variety of different phenotypic dimensions rather than a syndrome 
encompassing a range of heterogeneous distinct diseases (Confavereux and Vukusic, 2006). 
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1.1.2 Clinical presentations and diagnosis  
In general, the diagnosis of MS requires objective evidence of CNS lesions disseminated in 
time and space, with alternative explanations considered and excluded (Compston and Coles, 
2008; Thompson et al., 2018b). The diagnostic process relies on the presenting neurological 
symptoms and signs supported by paraclinical testing, especially MRI findings (Karussis, 
2013; Brownlee et al., 2017). Episodes of neurological dysfunction may be acute or subacute 
and spontaneous remit (Miller et al., 2005; Scalfari et al., 2010). By contrast, the onset of 
PPMS, as its name implies, is slowly progressive from the onset, with the symptoms 
continuously deteriorating over time (Kremenchutzky et al., 2006). The diagnosis of MS is 
clinical and using criteria that have developed over the years beginning with the Schumacher 
and Poser Criteria (Schumacher et al., 1965; Poser et al., 1983) and continue to evolve in the 
form of the various revisions of the McDonald criteria (McDonald et al., 2001; Polman et al., 
2005; Polman et al., 2011; Thompson et al., 2018a). Of note, these criteria all necessitate the 
exclusion of other CNS demyelinating diseases, such as neuromyelitis optica spectrum 
disorder, neurosarcoidosis, CNS vasculitis and connective tissue disorders, all of which can 
mimic MS (Solomon et al., 2016; Brownlee et al., 2017). 
Given that brain MRI abnormality is found in nearly all established MS patients and over 
80% of the CIS cases, and that MRI is necessary for differential diagnosis to exclude other 
demyelinating and non-demyelinating diseases, MRI remains the most crucial diagnostic tool 
for the disease (Fisniku et al., 2008; Wattjes et al., 2015). The MRI evidence suggestive of 
MS includes multifocal T2-hyperintensity, which is typically found in periventricular, 
juxtacortical and infratentorial regions of white matter (Polman et al., 2011; Rovira et al., 
2015). Apart from brain MRI, since spinal cord lesions may also present in many MS 
patients, spinal cord MRI is recommended to confirm the dissemination in space and to 
exclude alternative spinal cord diseases, when brain MRI findings are not sufficient for the 
diagnosis of MS (Sombekke et al., 2013). Non-enhancing hypointensity on T1-weighted 
images are more common in progressive subtypes and patients with long disease duration and 
are indicative of chronic lesions of an established MS disease process (Filippi et al., 2016). 
Simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesion 
either on a single scan or on follow-up scan demonstrates dissemination in time and thereby 
facilitate the diagnosis, especially when there’s only one clinical attack (Milo and Miller, 
2014).  
In most cases, cerebrospinal fluid (CSF) examination is not necessary as a confident 
diagnosis can usually be made based on typical clinical and MRI findings (Tintore et al., 
2015). Supportive CSF findings features such an elevated IgG index and the presence of 
oligoclonal bands, together with nearly normal white blood cell count, glucose and protein, 
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occur in most but not all patients. In many clinical diagnostic criteria CSF changes are 
essential to make the diagnosis of PPMS; although it is important to recognize that changes 
such as oligoclonal bands can be found in other neuro-inflammatory diseases; necessitating 
circumspect interpretation (Karussis, 2014).  
1.1.3 Management  
Over the past 20 years, a range of MS disease-modifying therapies have emerged, these 
agents have been shown to reduce the rate of relapses and probably also slow the rate of 
disability progression (Comi et al., 2017). The wide range of agents that are now available 
has made therapeutic choices increasingly complex (Montalban et al., 2018). The escalation 
strategy, one of the two therapeutic approaches available in current clinical settings, entails 
starting with a first-line treatment and escalating to a second-line treatment which is 
potentially more dangerous when relapses continue to occur (Thompson et al., 2018b). By 
contrast, in the highly active and rapidly evolving cases, an induction strategy, in which a 
highly effective treatment is used from the onset to achieve a persistent disease remission, is 
more often appropriate (Thompson et al., 2018b). 
All the currently approved disease-modifying therapies for RRMS have inflammation related 
mechanisms of action. A summary of FDA-approved drugs for RRMS could be found in 
Table 1.1.3 (Havrdova et al., 2009; Giovannoni et al., 2010; Leist et al., 2014; Cohen et al., 
2015; Kalincik et al., 2015; Kalincik et al., 2017; Wiendl et al., 2017; Baecher-Allan et al., 
2018). These agents have differing modes of action including reducing auto-reactive 
Th1/Th17 cells, inducing regulatory T cells, impeding the trafficking of immune cells, and 
modulating B cell activities. The anti-inflammatory efficacy and adverse effect burden vary 
between agents, with an inevitable inverse correlation (Bloomgren et al., 2012; Plavina et al., 
2014; Gagne Brosseau et al., 2016), as shown in Figure 1.1.3, which is adapted from the 
presentation by Alastair Compston at the ECTRIMS 2018 conference.  
Drug (Date of 
Approval) 
Category  Mechanisms 
Interferon β-
1b/1a (1993) 
Injectable drug Naturally occurring cytokine which reduces antigen presentation 
and T cell proliferation, alters cytokine expression, restores 
suppressor function 
Glatiramer 
acetate (1997) 
Injectable drug A mixture of short polypeptides, which activates the anti-
inflammatory glatiramer acetate-specific lymphocytes 
Teriflunomide 
(2012) 
Oral drug The metabolite of leflunomide, which inhibits the proliferation of 
autoreactive B and T cells 
Dimethyl 
fumarate (2013) 
Oral drug Inhibiting the transcription factor nuclear-factor-κB to reduce the 
release of inflammatory cytokines; activating the transcription 
错误!使用“开始”选项卡将 Heading 2 应用于要在此处显示的文字。 错误!
使用“开始”选项卡将 Heading 2 应用于要在此处显示的文字。 
7 
 
factor nuclear-factor-E2-related factor 2 to have an anti-oxidant 
effect 
Fingolimod 
(2010) 
Oral drug Acting as a functional antagonist of sphingosine 1-phosphate 
receptors, on which lymphocytes are dependent to egress from the 
lymphoid tissues, consequently resulting in a decrease of circulating 
lymphocyte number 
Cladribine (2017) Oral drug Synthetic deoxyadenosine analogue, which depletes B and T cells 
Natalizumab 
(2004) 
Monoclonal 
antibodies 
A humanized monoclonal antibody that acts by blocking α-4 
integrin to prevent lymphocytes from entering the CNS across the 
blood–brain barrier 
Alemtuzumab 
(2014) 
Monoclonal 
antibodies 
A humanized monoclonal antibody against CD52, which results in 
a long-lasting depletion of B and T cells 
Daclizumab 
(2016) 
Monoclonal 
antibodies 
A monoclonal antibody acting as an interleukin-2 inhibitor 
(withdrawn in March 2018 due to reports of adverse events) 
Ocrelizumab 
(2017) 
Monoclonal 
antibodies 
A humanized monoclonal antibody directed against CD20 
Table 1.1.3. Drugs for RRMS. 
 
Figure 1.1.3. Safety versus efficacy of currently available drugs for MS.  
It should be noted that the predominance of inflammatory mechanisms seen during the initial 
stages of the disease tends to decline with time, which partly explains the variable declining 
efficacy of currently approved disease-modifying therapies among patients (Giovannoni et 
al., 2017). In the light of this, early treatment with therapies that can reshape the immune 
system has been shown to improve longevity and reduce the rate of evolving to secondary 
progressive MS (Grossman et al., 2016). Such variability in response to drugs and the risk of 
having serious adverse effects is also likely to be influenced by genetic variation (Pistono et 
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al., 2017). In this context, the methods which evaluate how a person’s genomic makeup 
affects their response to therapies could in theory considerably facilitate the decision-making 
by clinicians, thereby helping patients receive the most optimal personalized treatment (Comi 
et al., 2017).  
In contrast to the advances in treatment for RRMS, it remains the case that there is a lack of 
effective treatments for the progressive forms of the disease (Salvetti et al., 2015; Feinstein et 
al., 2015). The currently approved anti-inflammatory drugs, which target the adaptive 
immune system in the peripheral as opposed to the compartmentalized immune responses in 
CNS, have little effects on the progressive aspects of MS (Lorscheider et al., 2017). In 
various phase 2 and phase 3 clinical trials of interferon beta-1, glatiramer acetate, 
natalizumab, and rituximab, there has been a suggestion that these agents prevent the 
deterioration of disability (Salzer et al., 2016; Kapoor et al., 2018; Palace et al., 2018), 
although the benefits of oral fingolimod in slowing disease progression in PPMS seem 
modest and remain controversial (Ontaneda et al., 2015; Lublin et al., 2016).  Currently 
Ocrelizumab is the only licensed agent for the treatment of primary progressive MS 
(Montalban et al., 2017), but the phase 3 results with siponimod are also promising (Kappos 
et al., 2017). The mechanisms by which these drugs influence MS progression are not well 
understood but are likely to reflect their anti-inflammatory effects rather than on effect on 
neurodegeneration itself (Beacher-Allan et al., 2018). The efficacy of re-myelinating drugs in 
MS patients has also been tested in one of the recent randomized trails (Green et al., 2017). 
Nevertheless, currently the aims of the management for progressive MS centre on minimizing 
symptoms and improving functions, which include weakness and fatigue, balance and 
mobility impairment, ataxia, spasticity, depression, pain, reduced cardiovascular fitness, 
cognitive deficits, bladder dysfunction, and pseudobulbar affect (Thompson et al., 2010; 
Amato et al., 2013; Gunn et al., 2015; Phe et al., 2016; Otero-Romero et al., 2016; Peyro 
Saint Paul et al., 2016; Motl et. al., 2017). Available data indicate that treatments for the 
progressive form of MS are likely to be most effective early in the disease, which affirms the 
importance of early diagnosis.  A range of strategies have been suggested to address 
progressive aspects of the disease including immune-regulatory drugs, aimed at preventing 
the compartmentalized autoimmunity from developing in the CNS, in addition to approaches 
targeting innate immune responses and neurodegeneration (Beacher-Allan et al., 2018). 
1.2 Epidemiology and evidence for environmental factors 
1.2.1 Epidemiology of MS 
The total number of people with MS worldwide is estimated to be around 2.3 million, 
however, this may well be underestimated given the relative lack of data from China and 
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African countries (Wasay et al., 2006; Thompson et al., 2018). The prevalence of MS is 
unevenly distributed globally, and generally displays a latitudinal gradient, ranging from 
2.1/100,000 in sub-Saharan Africa and 2.2/100,000 in Eastern Asia, to 108/100,000 in 
northern/central Europe and 140/100,000 in North America (Koch-Henriksen and Sorensen, 
2011; Browne et al., 2014). The prevalence also differs between distinct ethnic groups, with 
risk in Caucasians being relatively higher than in Afro-Caribbean and distinctly higher than 
in east Asians (Koch-Henriksen and Sorensen, 2010). The uneven distribution of the disease 
thus likely reflects the influence of both genetic and environmental factors, and the interplay 
between them.  
In addition to the striking geographical distribution of the disease, it has also been noted that 
MS most often develops in young adults rather than in children or the elderly and affects 
females far more often than males (Leray et al., 2016). Patients with PPMS generally present 
at an older age (mean 40) than patients with RRMS (mean 30) and have less of a gender 
difference (Antel et al., 2012). The gender-preference most likely reflects the higher 
frequency of relapses found in female patients (Kalincik et al., 2013). Interestingly, it has 
been indicated by migration studies that the prevalence among immigrants from low-risk to 
high-risk regions in childhood tend to develop into similar rate as that of the indigenous 
population and vice versa (Ascherio and Munger, 2016), which support the roles of 
environmental factors contributing to the aetiology of MS. However, the notion of one single 
dominant environmental factor causing MS has now been largely disregarded (Marrie, 2004; 
Hempel et al., 2017). Several environmental factors have been suggested to contribute to the 
risk of developing MS; most notably childhood exposure to Epstein-Barr virus (EBV) 
(Ascherio et al., 2010), vitamin D deficiency (Ascherio et al., 2014) and cigarette smoking 
(Handel et al., 2011).  
1.2.2 EBV infection, vitamin D deficiency and smoking 
According to the hygiene hypothesis, exposure to infection during early childhood introduce 
by the order siblings should reduce the risk of developing allergic and autoimmune diseases 
(Bach, 2002). However, in a longitudinal, population-based cohort study, no relation was 
found between birth order and MS risk, and there was insufficient evidence supporting the 
hygiene hypothesis in MS (Sadovnick et al., 2005). On the other hand, it has been suggested 
that viral infection, particularly of the gastro-intestinal tract and upper respiratory tract, can 
increase the activity of the disease (Andersen et al., 1993; Buljevac et al., 2002). It has also 
been suggested that the gut microbiome could be involved in triggering autoimmunity 
(Baecher-Allan et al., 2018). Among the various proposed infectious agents that might be 
involved in the aetiology of MS the best supported is undoubtedly EBV. Notably, the 
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association of EBV infection with MS seems to have a critical time window, with infection 
during adolescence and early adulthood but not childhood being relevant to the disease 
predisposition (Olsson et al., 2017). In support of this, an age dependent association between 
the elevation of EBV antibody titters and the increased risk of MS has also been reported 
(Levin et al., 2005). Accordingly, the risk is about 15 times higher among individuals 
infected during childhood when compared with unaffected individuals, and approximately 30 
times higher for those infected in adolescence or later (Ascherio, 2013). Primary EBV 
infection during childhood is typically asymptomatic but sometimes manifests as infectious 
mononucleosis when the infection occurs during early adulthood (Ascherio et al., 2010). 
Although the molecular basis is not completely clear, it has been suggested that the immune 
response against the virus might cross-reacts with myelin as a result of molecular mimicry 
(Lang et al., 2002). In a recent study, it has been shown that EBV infection can prevent a 
myelin oligodendrocyte glycoprotein epitope from being degraded, in a manner that involves 
cross-presentation of the disease-relevant epitopes to CD8+ CD56+ T cells (Morandi et al., 
2017). However, evidence regarding whether EBV RNA or protein is present in the CNS of 
MS patients remains controversial (Sargsyan et al., 2010; Lossius et al., 2014), and a lack of 
suitable experimental models makes it difficult to confirm any causal role of EBV in 
triggering the disease. It has been suggested alternatively that, since EBV infection is also 
known to be correlated with other autoimmune diseases, instead of mimicking specific 
epitopes, EBV may rather have a more general role in the dysregulation of the immune 
system (Dendrou et al., 2015). It is clear that the exact role played by EBV in MS 
predisposition needs to be further clarified.  
Besides viral infection, dietary and lifestyle-associated factors have also been shown to 
contribute to MS predisposition. It has been suggested that the differences in MS prevalence 
with geographical latitude might at least be partially explained by differences in the amount 
of sunlight exposure at different latitudes and the corresponding differences in vitamin D 
level (Simpson et al., 2011; Belbasis et al., 2015). In humans, the major natural source of 
vitamin D is via its synthesis in the skin from cholesterol, the chemical reaction of which 
depends on sun exposure. Since the conversion of vitamin D to its active metabolite relies on 
ultraviolet radiation (UVR), a lack of sunlight exposure would lead to a deficiency of vitamin 
D (Pantazou et al., 2015), however it turns out to be tricky to distinguish the relative 
importance of these two factors. Nonetheless, long term studies have suggested that higher 
serum 25(OH)D level is associated with decreased MS incidence and long-term disease 
activities (Ascherio et al., 2014); similarly, increased exposure to UVR is also associated with 
lower risk of MS (Simpson et al., 2011). Early life obesity is also associated with an 
increased risk of the disease particularly in women; a difference which could be due, at least 
in part, to the decreased bioavailability of vitamin D among obese individuals (Gianfrancesco 
and Barcellos, 2016). However, it should be noted that a direct link between the risk of MS 
and neonatal vitamin D deficiency is currently lacking (Ueda et al., 2014). It has been 
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suggested that vitamin D may have broad influences on immunity, such as suppressing 
lymphocyte proliferation and skewing T cells towards regulatory instead of inflammatory 
responses (Aranow, 2011). Another study has demonstrated that vitamin D could interact 
with HLA-DRB1*15 gene promoter via an MHC vitamin D response element (Ramagopalan 
et al., 2009). In the context of these data it has been suggested that correcting vitamin D 
insufficiency through dietary supplementation could be beneficial in preventing MS and 
could be easily achieved (Ascherio et al., 2012). 
The association between MS and smoking has also been recognized, with smoking conferring 
a relatively modest influence on MS predisposition (risk ratio 1.48, 95%confidence interval 
1.35-1.63) (Handel et al., 2011). The risk related to smoking is more prominent in male than 
female, and increases with intensity and duration (Belbasis et al., 2015). The speculative 
mechanisms that have been proposed to explain the association between smoking and MS 
include the activation of lung resident CD4+ antigen-specific autoimmune T cells or that 
smoking might compromise of the blood-brain barrier (van der Mei et al., 2011). Like other 
environmental risk factors discussed above, although the exact molecular mechanisms remain 
unclear, encouraging patients to quit smoking could be one of the most effective public health 
interventions to reduce the incidence of MS, and has some support from cross-sectional study 
on smoking cessation in MS (Ramanujam et al., 2015).  
1.3 Genetic factors 
1.3.1 Overview 
Multiple sclerosis does not follow a Mendelian pattern of inheritance, but rather clusters 
within families (Goris et al., 2012). The familial recurrence rate falls geometrically with the 
degree of relatedness, ranging from roughly 25% among monozygotic twins, to 5-3% among 
dizygotic twins and other first-degree relatives and 1% in second-/third-degree relatives 
(Robertson et al., 1996; Robertson et al., 1996’; O’Gorman et al., 2013). The pattern of 
familial recurrence risk in MS suggests a polygenic model in which risk is determined by a 
single moderate-effect common allele [odds ratio (OR) near 3 or 4] and a great many other 
alleles of much smaller effect size (OR < 1.5) (Gourraud et al., 2012). It has also been 
suggested that uncommon genetic variants might make considerable contribution to the 
heritability of autoimmune diseases, i.e. that the susceptibility may be partly determined by 
rare variants of large effect size (Goris et al., 2012). However, a recent large multi-cohort 
study that genotyped over 150,000 coding variants found only a hand full of associated low-
frequency variants and none of these had very large effect (International Multiple Sclerosis 
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Genetics Consortium, 2018). To date no Mendelian forms of MS have been identified 
(Hollenbach and Oksenberg, 2015), and it has been noted that such variants are unlikely to 
drive disease expression in complex diseases (Zenewicz et al., 2010). In summary, it is likely 
that both common and rare variants will influence the risk of MS, with some variants exerting 
larger effects than others but it is unlikely that any variant exerts a very large effect.  
1.3.2 MHC class II molecules 
The strongest genetic association with MS maps to the major histocompatibility complex 
(MHC) region on chromosome 6p21 and was first identified over 40 years ago (Jersild et al., 
1972). This 3.6-Mb region contains over 250 genes including the highly polymorphic human 
leukocyte antigen (HLA) genes (Olerup and Hillert, 1991; Gutierrez et al., 2016). The 
extensive long-range linkage disequilibrium (LD) that exists across this region has made 
pinpointing which alleles are driving the association difficult (Gregersen et al., 2006). With 
the development of high-throughput genotyping technologies, fine mapping efforts have 
confirmed that the strongest susceptibility signal is almost certainly driven by the HLA-
DRB1*15:01 allele (Moutsianas et al., 2015).  
The frequencies of HLA-DRB1*15:01 is relatively higher in European and Asian populations 
(over 10%), but very low elsewhere (Hollenbach and Oksenberg, 2015). The partially 
dominant risk effect from this allele has been well characterized, with an estimated OR value 
of 3.92 (Moutsianas et al., 2015). Carriage of this haplotype has been suggested to be 
associated with disease severity markers, and with the presence of oligoclonal bands in the 
CSF (Okuda et al., 2009), which has not yet been confirmed. Except for the age at onset, no 
consistent association was found between any aspect of disease phenotype and HLA variants, 
suggesting that the later only has weak, if any, influence on MS disease features (Moutsianas 
et al., 2015). 
Apart from HLA-DRB1*15:01, there are multiple additional independently associated HLA 
and non-HLA alleles in the MHC region. Some exert risk effects, such as the class II alleles 
HLA-DRB1*03:01, HLA-DRB1*13:03, HLA-DRB1*08:01 and HLA-DQB1*03:02, 
whereas others exert protective effects, including the class I alleles HLA-A*02:01, HLA-
B*38:01 and HLA-B*55:01 (Sawcer et al., 2011; Moutsianas et al., 2015). In the most recent 
MS genome-wide association study (GWAS) meta-analysis, 32 independent associations in 
the extended region of MHC were suggested (International Multiple Sclerosis Genetics 
Consortium, 2017). However, this analysis failed to correct for dominance effects in HLA 
alleles and to date many of the alleles in this list remain unconfirmed. In addition to marginal 
effects, some of HLA alleles were also found to modulate the effects of others by the 
interaction, in particular HLA-DQA1*01:01–HLA-DRB1*15:01 and HLA-DQB1*03:01–
HLA-DQB1*03:02 (Moutsianas et al., 2015). However, no evidence was found for 
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interactions between any of the HLA risk alleles and the non-MHC risk variants; the 
modulating effects of polygenic epistasis on major HLA allele risk for MS also turned out to 
be minimal (Moutsianas et al., 2015). Overall the HLA locus accounts for about 10.5% of the 
heritability of MS (Hollenbach and Oksenberg, 2015).  
1.3.3 GWAS and non-HLA variants 
In addition to HLA, GWAS, which involves genotyping several hundred thousand SNPs 
throughout the genome in large case-control cohorts, has led to the identification of over 200 
common variants of modest effect sizes (International Multiple Sclerosis Genetics 
Consortium, 2017). These include variants related to IL-2RA and IL-7RA, the first two genes 
identified outside the MHC regions (Hafler et al., 2007; Gregory et al., 2007). However, it is 
important to remember that GWAS identify sets of tightly correlated variants rather than 
individual causal variants; sets of variants that often span a region containing many potential 
candidate genes (Beecham et al., 2013). As the genomic regions implicated by these risk loci 
are extensive, the task of identifying functionally relevant genes has turned out to be difficult 
(Sawcer et al., 2014).  
In some complex traits screening for rare protein-coding variants has proven to be helpful in 
defining candidate genes within risk loci and has thereby provided insights into the 
mechanisms of the disease (Tasan et al., 2015; Gutierrez-Arcelus et al., 2016). In MS follow-
up efforts such as the Immunochip (Beecham et al., 2013) and the Exomechip (International 
Multiple Sclerosis Genetics Consortium, 2018) have advanced fine mapping and refined 
understanding of the underlying allelic structure (Cortes and Brown, 2011; Swacer et al., 
2014). Most recently, the meta-analysis has identified over 200 modest effect common 
autosomal susceptibility variants that lie outside MHC and one chromosome X variant 
(International Multiple Sclerosis Genetics Consortium, 2017; 2018). Most of these variants 
map to non-coding regulatory regions of genes with immunological function, and many of 
these variants are also associated with other autoimmune diseases (Farh et al., 2015). It has 
been suggested that the genetic burden of MS risk alleles might be helpful in a clinical setting 
(De Jager et al., 2009; Gourraud et al., 2011; Isobe et al., 2016). However, given the low 
prevalence and the modest familial clustering seen in MS, such approaches are unlikely to be 
useful in helping predict who will develop MS in large population; except perhaps in extreme 
circumstances (Sawcer et al., 2010; 2014).  
The genetic architecture of MS susceptibility highlights the prominent role of immune system 
in disease predisposition (Sawcer et al., 2011), and thereby provides some of the strongest 
primary evidence supporting the view that MS is an immune-mediated disease. The genes 
implicated by the associated loci identified to date cluster in key immunological pathways 
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involved in lymphocyte activation, receptor signalling, cytokine production and co-
stimulation (Sawcer et al., 2011; Beecham et al., 2013). In the T cell activation assay 
analysing individuals with different ancestry, researchers observed an inter-individual 
variability in the activation of T helper cells, with clear biases according to their ethnic 
origins (Ye et al., 2014). It is notable that correlation between MS associated variants and 
regulatory epigenetic feature is almost exclusively found in immune cells (Roederer et al., 
2015). In contrast to the overlap in risk variants seen between MS and other autoimmune 
diseases, there is very little such sharing with other neurodegenerative diseases such as 
Alzheimer’s or Parkinson’s disease (Baecher-Allan et al., 2018).  
In conclusion, the available data suggests that MS susceptibility is determined polygenically, 
with some variants influencing vulnerability to autoimmunity in general and others defining a 
CNS specificity, perhaps by influencing the T cell repertoire (Dendrou et al., 2015). 
Collectively the associated variants identified to date account for about 25% of the 
heritability, with 20% attributable to common genetic variants and 5% to coding low-
frequency variants which cannot be captured by GWAS (International Multiple Sclerosis 
Genetics Consortium, 2017; 2018). As in other complex genetic diseases, the so-called 
“missing heritability” most likely reflects as yet undiscovered risk variants with lesser effects 
and frequency but might also be due to the interactions with environmental factors (Koch et 
al., 2013; Olsson et al., 2017).  
1.4 Pathogenesis 
1.4.1 Inflammation 
As noted above, the clinical presentation of MS can include a broad array of neurological 
signs and symptoms, depending upon both the location and extent of the CNS lesions. For 
example, it has been shown that cortical inflammatory lesion load is associated with the 
physical and cognitive disability progression over time (Calabrese et al., 2012). While the 
progressive form of MS involves diffuse immunological processes and neurodegeneration, 
the underlying pathological process in RRMS is multifocal and primarily inflammatory 
(Ciccarelli et al., 2014). In the early stages of the disease the pathology is characterized by 
perivenular infiltration of B and T lymphocytes, which migrate across the compromised 
blood-brain barrier (Lucchinetti et al., 2005). Whereas in the progressive stages, chronic 
demyelination and trans-synaptic degeneration develop, perhaps as results of microglial 
activation (Lucchinetti et al., 2011; Calabrese et al., 2012). The pathogenesis of MS is thus a 
gradual process, that involves inflammation, neurodegeneration and a failure of restoration, 
with inflammation being the trigger of the pathological cascade.  
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Given that the inflammation in MS affects the CNS, it has been suggested that the 
lymphocytes are selectively recruited by autoantigens specifically expressed in the CNS 
(Ransohoff and Engelhardt, 2012), although presently how the immune responses are 
initiated and maintained in MS is unclear, and the antigen specificity is unresolved. As no 
predominant exogenous risk factor has been identified so far, it remains debated whether MS 
is triggered in the periphery or centrally. According to the outside-in model, during the initial 
stages of lesion formation, autoreactive lymphocytes activated in the peripheral cross the 
blood-brain barrier and lead to an aberrant immune response against CNS (Hohlfeld and 
Wekerle, 2004). Under the alternate inside-out model it is hypothesised that some primary 
CNS infection or other neuronal disturbance leads to the release of CNS antigens which 
subsequently trigger an autoimmune response targeting CNS (Trapp and Nave, 2008). Both 
scenarios result in a deleterious cycle of CNS tissue damages, release of antigens to the 
peripheral, priming of peripheral immune responses, and invasion of autoreactive 
lymphocytes into CNS (Friese et al., 2014). As lymphocytes, plasma cells, and macrophages 
accumulate, the inflammatory cytokines they release further amplify the immune response, 
recruiting and activating naïve microglia and ultimately leading to neuronal dysfunction and 
cell death (Heneka et al., 2014). However, the association between inflammation and active 
lesions does not exclude the possibility that the inflammation activity is secondary, and the 
primary event is tissue damage. Nonetheless, both genetic analysis and pathological findings 
have pointed to the prominent roles played by immune system in MS pathogenesis. 
1.4.2 Neurodegeneration 
The inflammatory activities which predominate in the early stages are believed to trigger the 
cascade of events, including microglia activation, chronic oxidative injuries, mitochondrial 
damage and accumulation of toxic iron that drive progressive neurodegeneration (Mahad et 
al., 2015). In line with this, evidence suggests that the extent of active demyelination and 
axonal damage is positively related to the extent of lymphocyte infiltration (Frischer et al., 
2009). During the past decade, our understanding of the molecular mechanisms behind 
neurodegeneration in MS has advanced considerably. It is now recognized that microglia in 
active MS lesions form close contact with myelin sheaths of the degenerating neurons, and 
express molecules associated with the production of reactive oxygen species (ROS) 
(Ontaneda et al., 2017). In cases of chronic oligodendrocyte damage and axonal 
demyelination, axons lose structural and trophic support, which exposes them to ROS and 
inflammatory mediators in the microenvironment (Lucchinetti et al., 2005). These also give 
rise to changes of sodium channels expressed along demyelinated axons (Craner et al., 2004; 
Friese et al., 2007), and consequently, saltatory impulse conduction is replaced by continuous 
conduction, resulting in accumulation of sodium in the cytoplasm. These changes lead to the 
16 错误!使用“开始”选项卡将 Heading 1 应用于要在此处显示的文字。 
 
reverse operation of the sodium-calcium exchanger, resulting in calcium overload, activation 
of calpains and axonal cytoskeleton proteolysis (Trapp and Stys, 2009).  
In addition to the changes noted above, the oxidative injury also results in mitochondrial 
dysfunction, which includes impaired mitochondrial transport, mitochondrial DNA mutation, 
and increased ROS production by mitochondrial (Haider et al., 2011). These lead to increased 
cellular energy demand, failure of energy production, imbalance of ionic homoeostasis and 
accumulation of various cytotoxic species (Lassmann et al., 2012). Given the geometry of the 
neuron-axon structure, which makes efficient distribution of ATP production units 
challenging, axons are particularly susceptible to mitochondrial dysfunction (Friese et al., 
2014). The consequences of mitochondrial damage are twofold: firstly, it leads to energy 
deficiency and histotoxic hypoxia, which amplify the energy deficiency caused by 
inflammation, and result in axonal transection and cell death when the injury passes certain 
threshold; secondly, it disturbs respiratory chain function and liberates electrons, which react 
with oxygen, causing vicious cycles in the process of oxidative damage (Fischer et al., 2012; 
Mahad et al., 2015). In addition to the age-dependent accumulation of iron in brains, divalent 
cations (e.g. Fe2+ and Cu2+) liberated from damaged oligodendrocytes and myelin in MS 
lesions also act as an amplifier of oxidative injury by converting H2O2 into highly reactive 
hydroxyl molecules via the Fenton reaction (Mahad et al., 2015). Collectively, the increased 
energy demand and reduced ATP production induce a state of chronic hypoxia that results in 
the necrosis of demyelinated axons.  
Ultimately apoptosis and DNA damage lead to extensive axonal and neuronal loss resulting 
in the progressive phase of MS (Kornek et al., 2000). The diffuse infiltration of lymphocytes 
and monocytes that occurs in the compartmentalised inflammatory lesions can also cause 
widespread white matter injury (Howell et al., 2011). In addition to the compartmentalized 
immune responses, dysregulation of astrocyte and microglial activation also contribute to the 
diffuse tissue injury (van Horssen et al., 2012; Schreiner et al., 2015). Although axons and 
neurons are generally preserved in the early stages, the gradual neuro-axonal loss ultimately 
results in brain atrophy and glial scars formed by astrocytes in white matter (Kutzelnigg et 
al., 2005), which contribute to the progression of MS at later stages.  
1.4.3 Failures of re-myelination 
Apart from neuro-axonal loss, astrocytic gliosis and demyelination, which are widely 
recognised as the hallmarks of MS pathology, the failure of re-myelination has also been 
recognized as a contributor to the disease progression (Popescu and Lucchinetti, 2012; Lemus 
et al., 2018). It has been demonstrated in mouse brain that prompt re-myelination could 
protect axons against axonal lost associated with demyelination (Irvine and Blakemore, 
2008). However, although oligodendrocyte precursors are abundant in lesions, the presence 
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of inhibitory factors and a lack of pro-myelination factors result in incomplete re-myelination 
in human (Chang et al., 2002). The newly formed myelinated internodes tend to be shorter 
and thinner than the original ones, and the axonal membrane demonstrates an increase of 
sodium channels following demyelination (Franklin and Ffrench-constant, 2008). As a result, 
the partially restored nerve conduction is less saltatory and more continuous, which leads to 
an increased energy demand and consequent changes in mitochondria (Ontaneda et al., 2017). 
In support of this, symptoms such as physiological fatigue and distortions of sensation could 
also be explained by the partially demyelinated axons which are incapable of transmitting fast 
trains of impulse and discharge spontaneously (Mahad et al., 2015). Moreover, the increased 
mechanical sensitivity, spontaneous discharge in facial nerve neurons and the failure of 
conduction in partially demyelinated pathways may also explain Lhermitte’s symptom, 
myokymia and Uhthoff phenomenon (Trapp et al., 2009). Thus, although compensation may 
occur spontaneously in MS, cycles of demyelination and unsuccessful re-myelination exhaust 
the capacity for tissue repair, and thereby account for various manifestations of MS. 
In summary, a series of immunological and neurodegenerative events, which act in concert 
and change in their relevance as the disease progresses, engender and sustain CNS damages 
during the development of MS. The acute inflammatory injuries mediated by infiltration of 
lymphocytes, the activation of microglia, the chronic degeneration of demyelinated axons, 
and a failure of re-myelination jointly contribute to the irreversible disability in MS. 
Therefore, a combination of anti-inflammatory, neuroprotective and regenerative strategies 
may all be beneficial in the treatment of MS in the future.  
1.5 Immunopathology of MS 
1.5.1 Overview 
As outlined in previous sections, genetic and pathological studies have pointed to 
inflammation as the driving force in the pathogenesis of MS. It is clear that both innate and 
adaptive immunity, contribute to the pathogenesis of MS (Hemmer et al., 2015). The two 
major cellular components of the adaptive immune system, T cells and B cells, can be further 
classified into different immune cell subtypes by various surface markers. B cells develop in 
the bone marrow, whereas T cells mature in the thymus and interact with antigen presenting 
cells (APCs) for further activation (Crotty, 2015). Highly variable somatic rearrangements in 
α and β T cell receptor (TCR) chain genes enable T cells to recognize antigens and react to a 
wide range of antigens, and in turn the relevant T cells being activated when their cognate 
antigen is presented in conjunction with MHC class II molecules specialised APCs 
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(Kambayashi and Laufer, 2014). This interaction is supported by a series of co-receptors such 
as CD3 and CD4 (Chen and Flies, 2013). In addition, the activation of CD4+ T cell also 
necessitates additional co-stimulation from CD80/CD86 expressed by APCs, which are the 
ligands for CD28 and CTLA4 on T cells (Chen and Flies, 2013; Yuseff et al., 2013). B and T 
cell responses directed against self-antigens are limited by a range of central and peripheral 
self-tolerance mechanisms such as the elimination or inactivation of self-reacting clones 
(Gonsette, 2012). During the initiation of MS and the progression of the disease, these self-
tolerance immune mechanisms are compromised, and the activated microglia and 
macrophages induce autoreactive responses of T and B lymphocytes by secreting pro-
inflammatory cytokines, chemokines and free radicals, which amplify the autoimmunity 
against CNS.  
1.5.2 T cells 
The long-appreciated associations of HLA with MS and the presence of T cells within CNS 
lesions even in early stages of the disease support the notion that T cells play a critical role in 
the susceptibility of MS. In accordance with this notion, an expression quantitative trait locus 
(eQTL) study using purified monocytes and CD4+ T cells has demonstrated that the T cell 
specific eQTLs among susceptibility alleles are over-represented in autoimmune diseases 
(Raj et al., 2014). Moreover, in animal MS models, the autoreactive myelin-specific CD4+ T 
cells has long been recognized as a key pathogenic effector and a major therapeutic target 
(Hohlfeld et al., 2016). It has been proposed that, once activated in the periphery by the 
myelin protein-derived antigens, the autoreactive CD4+ T helper type 1 (Th1) cells and T 
helper type 17 (Th17) cells, which are the main T cell subtypes implicated in the disease, 
would upregulate their expression of cytokine receptors and secretion of pro-inflammatory 
cytokines (Dendrou et al., 2015). The therapeutic mechanisms of some of the first-line 
disease-modifying therapies (IFN-β, glatiramer acetate and dimethyl fumarate) are also 
thought to be associated with skewing T cell differentiation away from these subsets and 
towards a T helper type 2 (Th2) cell phenotype (Dendrou et al., 2015), which highlights the 
pathological roles played by these T cell subtypes. However, conflicting results also exist, as 
antibodies targeting the p40 subunit shared by IL-12 and IL-23 (ustekinumab), which are 
involved in Th1 and Th17 cell differentiation respectively, didn’t pass the phase II clinical 
trial (Segal et al., 2008). Such failure might be due to the incompatibility of EAE models with 
human studies or the diminished importance of the two cytokines at later stages of the 
disease.  
In comparison with CD4+ T helper cells, the precise contribution of CD8+ T cells is less clear. 
CD8+ T cells are more frequently found in the cortical demyelinating lesions of the white and 
grey matter than CD4+ T cells, and their numbers correlates with the degree of axonal damage 
(Frischer et al., 2009). The myelin-specific CD8+ T cells could be readily activated in CNS, a 
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quarter of which were found cable of producing IL-17 and IL-18 in the active lesions of MS 
patients (Willing et al., 2014). The long-lasting depletion of these autoreactive CD8+ T cells 
after autologous hematopoietic stem cell transplantation (aHSCT) implies that they might 
also play crucial part in the disease pathogenesis, although the exact mechanisms remain 
unclear at present (Abrahamsson et al., 2013). 
In addition, other relevant cell types might also participate in facilitating the infiltration and 
activation of T cells that cause damage in CNS. For instance, it has been shown that activated 
T cells could adhere to the endothelium and migrate across the blood-brain barrier by 
upregulating their expression of adhesion molecules and inducing reciprocal changes in 
endothelia cells (Dendrou et al., 2015). Once in the CNS, the autoreactive T cells could be 
further activated by local APCs such as microglia, which results in recruitment of 
inflammatory cells and activation of resident astrocytes and microglia (Kambayashi and 
Laufer, 2014). These infer that complex multi-cellular and environmental interactions are 
critically important contributing to MS pathogenesis, among which the interaction with B 
cells seems most prominent. 
1.5.3 B cells 
Although historically T cells have been considered as the most critical pathological drivers in 
MS, the effectiveness of selective B cell depletion with anti-CD20 antibodies (rituximab and 
ocrelizumab) in limiting disease activity has also highlighted the as yet incompletely 
understood roles played by B cells in MS pathogenesis. Since massive expansion of antigen-
specific lymphocytes from the precursor cells in lymph nodes requires the presence of 
professional APCs, it is well-appreciated that complex interplay exists between T cells and B 
cells. It has been demonstrated that MS patients have an increased number of B cells, most of 
which are memory B cells and plasmablasts, and that the number of plasmablasts in CSF 
correlates with oligoclonal antibodies and inflammatory activities (Cepok et al., 2005). In the 
phase III clinical trials (OPERA I and II) of ocrelizumab, the humanized monoclonal 
antibody selectively depleting CD20+ B cells resulted in lower rates of relapse and lesion 
progression in patients as compared with IFN-β (Hauser et al., 2017). In addition, treatment 
with potent immunosuppressive therapy and autologous hematopoietic cell transplantation 
have also been found to be effective among patients who had failed to benefit from other 
disease-modifying therapies (Nash et al., 2017). Such evidence supports the notion of B cells’ 
involvement in MS and the necessity for more comprehensive understanding of the 
interactions between B cells and T cells. 
Interestingly, most of the immune therapies for RRMS originally designed to target T cells 
are now known to impact B cell responses (Li and Bar-Or, 2018). Given that 
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autoantibody-producing, terminally differentiated plasma cells are not depleted by anti-CD20 
antibodies, and that the abnormal antibody profiles in the CSF remain largely unaffected after 
the depletion, the relevant mechanism is believed to be primarily dependent upon antibody-
independent roles of B cells (Hauser et al., 2008; Barr et al., 2012). Studies have also found 
that memory B cells from some RRMS patients respond to myelin–associated protein by 
eliciting T cell proliferation, IFN-γsecretion and Th17 responses against neuro-antigens 
(Harp et al., 2010; Ireland et al., 2016). In addition, an increased frequency of the pro-
inflammatory GM-CSF-expressing memory B cell subtype in MS patients has also been 
noted (Li et al., 2015). These imply the relevance of exploring the various B cell subtypes 
which are functionally distinct. 
Given the limited effectiveness of currently available disease-modifying treatments, cell-
based therapies have generated considerable interest as novel strategies for immune 
regulation in MS (Scolding et al., 2017). As mentioned previously, since the success of the B 
cell depletion therapy highlighted the immunomodulatory functions of B cells, it has been 
realised that the expression of MHC-II and the co-stimulatory molecules such as CD80 and 
CD86 maybe crucially involved in the aberrant activation of T cells in autoimmune diseases 
(Chen and Flies, 2013). The elimination of pro-inflammatory B cells could potentially lead to 
reduced Th1 and Th17 cell responses, thereby decreases disease activity (Dendrou et al., 
2015). Thus, the abovementioned findings warrant further investigations on the mechanisms 
related to B cells, including effector and regulatory functions of B cells. Given that CD40 
ligation is crucial for B cell activation, the following section focuses on this specific B cell 
activation pathway and the rationales for choosing it as the activation method in my study. 
1.5.4 CD40-CD40L pathway 
CD40, which belongs to the tumour necrosis factor (TNF) receptor superfamily, is 
constitutively expressed on APCs, such as B cells, microglia and macrophages, whereas 
CD40L is expressed on CD4+ T cells following TCR-MHC engagement (Elgueta et al., 
2009). CD40-CD40L interaction, when in combination with B cell receptor (BCR) signalling, 
is a critical signal for B cell proliferation, activation, immunoglobulin production, isotype 
switching, memory B cell transformation and germinal centres formation (Guo et al., 2017). 
In addition, engagement of CD40 by CD40L can induce upregulation of CD80, CD86, MHC 
class I and class II, and promote the secretion of pro-inflammatory cytokines, which further 
drive T cell differentiation and activation (Summers deLuca and Gommerman, 2012). It has 
been reported that stimulating memory B cells via BCR and CD40 in vitro mimics T cell 
dependent antigen stimulation (Chen and Flies, 2013). Enhanced proliferation and over-
production of IL-6, IFN-γ, IL-17 and TNF-α is seen in treatment-naïve RRMS patients as 
compared with that in healthy controls, whereas no difference was found in the expression of 
CD40 on B cells between MS patients and healthy controls (Duddy et al., 2004; Ireland et al., 
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2012; Chen et al., 2016). These imply that the CD40 pathway in B cells might be more 
sensitive to CD40 stimulation in MS patients. 
The CD40 pathway has also been implicated in a variety of other autoimmune diseases and 
disease models and is indicated as a promising therapeutic target (Huber et al., 2012; Crotty, 
2015). In the mouse model of MS, neutralizing CD40L with antibody was found to be 
effective in preventing experimental autoimmune encephalomyelitis (EAE), although its 
clinical potentials remain controversial due to the side effects (Gerritse et al., 1996; Kawai et 
al., 2000). Interestingly, although it is more often the case that the same variants influence the 
susceptibility of several autoimmune diseases in the same direction, some variants are 
protective for one disease but act as risk factors for others. For example, the allele of the 
CD40 SNP rs4810485 increases the risk of rheumatoid arthritis, but reduces the risk of MS 
(Raychaudhuri et al., 2008; Australia and New Zealand Multiple Sclerosis Genetics 
Consortium (ANZgene), 2009). These observations imply that the genetic basis of 
autoimmune diseases is more complex than merely enhancing the activation of immune cells, 
and that the relevant mechanisms are likely context-dependent. 
In work completed in my supervisor’s lab prior to me joining the group it was shown that the 
risk allele of rs4810485 lowered the expression of CD40 on B cells (Smets et al., 2018). 
These findings imply that the dysregulation of CD40 signalling might contribute to the hyper-
responsiveness of B cells when stimulated, and that CD40 might also be involved in 
regulatory mechanisms. In support of this, other researchers have shown that MS patients 
displayed considerably higher phosphorylated NF-kB level in memory and naïve B cells than 
healthy controls after CD40 stimulation, which could be partially modulated by glatiramer 
acetate therapy and IFN-β-1a/Cellcept combination therapy, and that MS risk loci are 
enriched for the binding sites of NF-κB (Chen et al., 2016). In line with these observations, 
it has also been found that two genetic variants are associated with enhanced NF-κB 
expression and signalling response after stimulation with TNF-α in MS patients (Housley et 
al., 2015). These findings highlight the relevance of investigating the genotypic influences on 
B cell when activated via CD40 under in vitro conditions. 
1.5.5 Regulatory B cells 
It is now widely accepted that, apart from producing antibodies upon activation, B cells also 
have antibody-independent functions, such as producing pro-/anti-inflammatory cytokines in 
response to stimuli (Bao and Cao, 2014; Li et al., 2017); for example, IL-10-producing B 
cells represent a major subset of regulatory B cells (Bregs) that suppress autoimmune 
responses (Filatreau et al., 2008; Rosser and Mauri, 2015). It has been suggested that the 
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regulatory capacity of B cells is dependent on their production of IL-10 and their ability to 
interact with pathogenic T cells. The clinical efficacy of B cell depletion therapy may be due 
in part to the repopulation of newly differentiated Bregs (Mauri and Ehrenstein, 2008; Mauri, 
2010). Given the relevance of Bregs in the regulation of immune responses, it is plausible 
that associated genetic risk factors exert their effects primarily in this B cell subtype.  
It is known that IL-10 has a central role in autoimmunity and infection by regulating the 
immune response to prevent excessive injuries to the host (Saraiva and O’Garra, 2010). In 
both human and mouse model, IL-10 has been found to attenuate the antigen presenting 
capacity of B cells by down-regulating CD86 expression, and thereby suppresses T cell 
proliferation (Matsumoto et al., 2014; Nova-Lamperti et al., 2016). The increase in CD86 
expression in ex vivo B cells that we found in our previous analysis might be associated with 
IL-10 and IL-10-producing Bregs. Furthermore, Bregs have also been shown to induce the 
differentiation of regulatory T cells that produce IL-10 and TGF-β and suppress Th1 and 
Th17 responses (Flores-Borja et al., 2013). Unlike in mouse models, currently no consensus 
has been reached regarding the surface markers used to define the Breg population in 
humans, although a variety of cell surface markers have been suggested (Yanaba et al., 2008; 
Blair et al., 2010; Khoder et al., 2014). The role of CD24hiCD38hi transitional B cells have 
turned out to be most promising, given its reliability in capturing the human IL-10+ Breg 
populations, and were used in this study (Blair et al., 2010).  
Lastly, it has been suggested that the induction of Bregs are also critically dependent on 
CD40-CD40L pathway (Vitale et al., 2010). Recent study has found that tolerant transplant 
patients exhibit higher IL-10 positivity among B cells after CD40 activation and reduced 
BCR signalling than healthy controls (Nova-Lamperti et al., 2017). By contrast, a reduced 
number of Bregs with impaired regulatory capacity were found in patients affected by 
autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE) (Bankó et al., 2017). In the context of these data it seemed likely that activating B cells 
using CD40 will provide disease relevant information. 
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Chapter 2 Previous works and study design 
2.1 Previous works 
The 2011 MS GWAS identified 57 non-MHC associated variants, three of which were 
identified within a 360kb region on chromosome 3q13 (Sawcer et al., 2011). This region 
contains several genes - IQCB1, EAF2, SLC15A2, ILDR1, CD86, CASR, CSTA and 
CCDC58. Given the critical role of CD86 within the adaptive immune system this seemed 
like a particularly strong candidate. It is notable that none of the lead associated SNPs in this 
region (rs9282641, rs4285028 and rs4308217) is correlated with any known missense coding 
variant in any of the nearby genes. Thus, like most other GWAS identified SNPs, it seemed 
more likely that these variants exert their influence by affecting gene expression rather than 
gene function (Sawcer et al., 2014).  
Given that genetic effects on regulation are often cell type and cell state specific, and that 
CD86 is primarily expressed by APCs, Dr Fiddes (my predecessor) started his research by 
measuring CD86 expression in different subtypes of B cells and monocytes using flow 
cytometry and correlated these with the associated genotypes. In addition, he also assessed 
the soluble forms of CD86 in serum and the expression at RNA level in each of the cell types. 
His work was based on peripheral blood mononuclear cells (PBMCs) from 162 healthy 
volunteers which were collected from Cambridge BioResource based on their genotype to 
provide a balanced representation of the possible allele combinations across the three 
associated CD86 SNPs. The surface expression of CD86 was successfully measured in B 
cells from 145 subjects and in monocytes from 144 subjects. Overall, Dr Fiddes found a 
positive association between the carriage of rs9282641 risk allele (G) and the proportion of B 
cells expressing CD86 (p=0.0015), whereas neither of the other two SNPs were found 
associated with CD86 expression in B cells, and none of the three SNPs were associated with 
CD86 expression in monocytes. No statistically significant association with any of the three 
SNPs were found in the soluble CD86 in serum or mRNA expression experiments. After I 
genotyped the DNA samples collected by Dr Fiddes at the SNP rs4810485, we found a 
negative association between CD40 expression and the carriage of MS associated risk allele 
T in B cells, with naïve B cell subtype having the lowest p value, which would be addressed 
in detail in the results chapter. This is in line with a previous study, which has also found that 
the carriage of MS CD40 risk allele results in significantly lower expression level of CD40 
on B cells (Field et al., 2015). 
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In addition, Dr Fiddes also examined CD86 surface expression in the main subtypes of B 
cells and monocytes, namely naïve (CD19+CD27-), class switched memory 
(CD19+CD27+IgD-) and non-class switched memory (CD19+CD27+IgD+) B cells, and 
classical (CD14hiCD16-), non-classical (CD14loCD16+) and intermediate (CD14hiCD16+) 
monocytes. No association between genotypes and the relative proportions of these subtypes 
within the B cell or monocyte populations was found for any of the three SNPs. However, 
among naïve B cell subtypes, it was found that the carriage of the risk allele at rs9282641 (G) 
is positively associated with the proportion of cells expressing CD86 (p=0.000056). In the 
other B cell subtypes, although a trend towards association between carriage of the risk allele 
of rs9282641 (G) and the proportion of cells expressing CD86 was found, which was 
nominally significant in class switched memory B cells, it did not survive the correction for 
multiple testing.  
In summary, these previous efforts have shown that, across different B cell subtypes, naïve 
cells (CD19+CD27-) displayed the most significant associations between the expression of 
CD86/CD40 and their respective SNPs. These results have not only confirmed the relevance 
of the two MS GWAS SNPs in association with the expression of CD86 and CD40, but also 
refined our target cell type to naïve B cells as the population of most interest.  
2.2 Overview of the research questions to be addressed 
Despite the success of GWAS in expanding the number of identified loci associated with MS, 
a comprehensive model of disease pathogenesis and an understanding of the mechanisms by 
which genetic risk variants confer susceptibility to the disease is currently missing. In 
general, genetic variation may influence gene transcription, DNA methylation, histone 
modifications, mRNA translation/stability, and protein production (Maurano et al., 2012). 
These cellular processes may affect or be affected by immunophenotypes, which in turn can 
influence the manifestation of the disease. Thus, to better appreciate the complexity of the 
association between the GWAS-identified variants and the pathogenesis of MS, a few 
questions need to be further addressed. 
As in cases of most diseased-associated SNPs identified by GWAS, it is still unclear how the 
genes are affected by the variants and which are the causal variants (Tasan et al., 2015). Since 
over 95% of the GWAS-identified association signals are located within “gene deserts” that 
don’t contain any protein-coding genes, it is likely that most of the underlying causal variants 
influence regulatory elements, such as enhancers/repressors (Zenewicz et al., 2010; Maurano 
et al., 2015). This view is supported by the findings that GWAS SNPs, especially those with 
lowest P value, are more likely to be enriched in promoter-interacting fragments (Mifsud et 
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al., 2015). In addition, such elements can also exert long-range effects on very distant genes, 
and many have context-specific effects (Schoenfelder et al., 2015).  
Thus, a critical follow-up step is to identify the in vivo and ex vivo cellular and molecular 
immune traits affected by the risk variants, including cell-type abundances, cell proliferation, 
signalling response, and cytokine production. As described above, previous efforts have 
shown that the two MS associated variants that respectively influence CD86 and CD40 
expression, do so primarily in naïve B cells. To further investigate the questions raised, the 
following three issues need to be addressed: defining the relevant cell types and cell states 
that are implicated in the MS variants, identifying the molecular pathways involved, and 
elucidating the downstream effects of the genetic factors. 
2.3 Relevant Cell types/states 
The human immune system is composed of hundreds of cell subtypes, the functions of which 
reflect differences in intracellular gene regulation (Maecker et al., 2012). Due to the 
polygenic nature of MS, it has been hypothesized that most genetic risk/protective alleles 
exert their effect on a limited number of cell types, and influence gene regulation in a cell 
type specific manner (Gutierrez et al., 2016). Also, since each cell type may take on a variety 
of states in response to different stimuli, and that a considerable proportion of eQTLs are 
exclusively found in very specific stimulated states (Nica and Dermitzakis, 2013), it may be 
necessary to ascertain which cellular states are relevant to the genetic regulatory variants. 
Notably, about two-third of the genes identified in MS GWAS are expressed by APCs, 
including MHC class II, CD86 and CD80 (Sawcer et al., 2011), whereas the association of 
their receptors/ligands such as TCR, CD28 and CTLA expressed by T cells are much 
underrepresented in various GWAS studies (Beecham et al., 2013). Such significant 
enrichment for cell type specific expression of genes in MS risk loci highlight the pertinence 
of defining the cell types involved. The correlated variants could either be local (cis eQTLs) 
or distant (trans eQTLs, typically defined as being more than 5Mb away or on a different 
chromosome) (Brynedal et al., 2017). Therefore, to understand the mechanisms by which 
individual alleles influence gene expression, it would certainly be helpful, and maybe 
essential, to define the cellular subtypes and states that are the most relevant to the disease. 
In order to more clearly define the B cell sub-types most strongly influenced by the MS 
associated SNPs I decided to include analysis of the CD24 and CD38 surface markers, which 
characterize the transitional B cell population that are believed to have regulatory capacity 
(Mauri and Bosma, 2012; Simon et al., 2016), and the CD24-CD38+ plasmablast. In addition, 
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it has also been suggested that human CD25+ B cells may have some immunomodulatory 
properties and have higher expression of co-stimulatory molecules than CD25- B cells 
(Brisslert et al., 2006; Amu et al., 2007; de Andrés et al., 2014). In view of these 
considerations I also included CD25 in my analysis. Given that epigenetic regulation of 
expression is often both cell type and cell state specific I also hypothesised that perhaps the 
influence of genotype on expression might be increased (or reduced) in stimulated rather than 
resting cell. To explore this, I wanted to use a stimulation method that would perhaps most 
closely resemble the stimulation that might occur in vivo. I therefore used CD40L-transfected 
L cells to co-culture with PBMCs for 3 days, with un-transfected L cells used as negative 
controls. With such experimental designs, I reasoned that I would be able to, firstly, 
investigate a wider range of B cell sub types than had been considered by Dr Fiddes and 
secondly, to establish whether stimulation resulted in any substantial change the impact of 
associated variants on expression.  
2.4 Molecular pathways involved 
I also reasoned that relying exclusively on cell surface expression might miss important 
functional heterogeneity within B cells. Accumulating evidence has suggested that the 
dysregulated cytokines secreted by B cells play an important role in the pathogenesis of MS 
(Mauri and Bosma, 2012; Rosser et al., 2014), a disease in which the deficiency of regulatory 
cytokines and the exaggerated production of pro-inflammatory mediators have been well 
appreciated (Li et al., 2015). It therefore seemed logical include some degree of cytokine 
analysis.  
Among the long list of potential cytokines that might be considered, the immunoregulatory 
cytokine IL-10 seemed particularly logical (Masanori et al., 2014). It has been described that 
tolerant kidney transplant patients exhibited higher percentages of IL-10-producing 
transitional B cells after dual-BCR/CD40L activation compared to healthy controls (Nova-
Lamperti et al., 2016). Conversely, following stimulation with CD40, transitional B cells 
isolated from SLE patients have demonstrated lower positivity of IL-10 relative to healthy 
controls, and their regulatory capacity was functionally impaired (Blair et al., 2010). These 
might be due in part to the fact that the cytokine production and response of B cells after 
activation might be affected by their immediate microenvironment and overall immune 
propensity (Vazquez et al., 2015). Besides IL-10, other cytokines have also been suggested to 
be involved in MS. For example, it has been shown that combined CD40 and BCR 
stimulation can enhance human B cells’ secretion of TNF-α, which is implicated in inducing 
Th1 and Th17 responses and inhibiting Treg suppression (Duddy et al. 2007; Iwamoto et al., 
2007). Furthermore, it has also been shown that B cells from MS patients produce 
significantly higher level of TNF-α upon such mode of activation (Duddy et al. 2007). In 
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addition, GM-CSF expressing B cells were found to be notably increased in MS patients, and 
co-express TNF-α and IL-6 but not IL-10 (Li et al., 2015). By contrast, IL-6 has been 
ascribed with both pro- and anti-inflammatory properties, and it has been shown that IL-10-
producing B cells can be induced by IL-6 (Rosser et al., 2014), although in EAE IL-6 
producing B cells have been shown to induce T cell polarization to Th17 (Vazquez et al., 
2015). It has also been found that B cells secret higher level of IL-6 in MS patients than in 
healthy controls, which could be normalized after Rituximab treatment among reconstituting 
B cells (Barr et al., 2012), and that blocking IL-6/IL-6R signals could attenuate the secretion 
of antigen-specific auto-antibodies by B cells from SLE patients (Xiong and Lahita, 2011).  
These studies implied that cytokines such as IL-10, TNF-α, GM-CSF and IL-6 are very likely 
be implicated in the molecular pathways relevant to MS pathogenesis, although whether these 
cytokines are produced by identical or different B cell subtypes is not clear. Moreover, these 
cytokines might also be involved in the modulation of the surface expression of CD86 and 
CD40. For example, it has been found that in both humans and in mouse model IL-10 
produced by B cells can attenuate the antigen presentation capacity of B-cells by down-
regulating CD86 expression on their surface (Mauri and Bosma, 2012). To better explain the 
genotypic difference of CD86 and CD40 expression under in vitro condition, it is necessary 
to include the relevant intracellular markers. Therefore, in addition to surface markers I also 
assayed the cytokines IL-10, TNF-α, IL-6 and GM-CSF. 
2.5 How T cells may respond to these genetic factors 
Traditionally MS has been considered as a T cell driven autoimmune disease (Dendrou et al., 
2015), however, as discussed above, evidence is now emerging which suggests that B cells 
may also be important, or even primary, perhaps by orchestrating T cells differentiation in a 
pro-inflammatory and self-reactive direction (Dendrou et al., 2015; Jackson et al., 2015). It 
has been suggested that dysregulated signalling of B cells could be sufficient to induce the 
initial break in tolerance and promote CD4+ T cell activation (Jackson et al., 2015). In this 
context, any genotypic effects on B cell expression of CD86 and CD40 should influence T 
cell expansion and differentiation.  
Contrary to the late involvement of T cells in immune responses, B cells could rapidly 
capture antigens via BCR without cleaving them into peptides, which enable them to function 
at an early phase and facilitate the recruitment of regulatory T cells (Tregs) till they become 
functional (Berthelot et al., 2012). A variety of cytokines produced by activated B cells could 
influence T cell differentiation. For instance, it has been found that the balance of T cell 
differentiation into Th17 cells and Tregs depends on IL-6 signalling, overproduction or 
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dysregulation of which could lead to autoimmune diseases including MS and RA (Kimura 
and Kishimoto, 2010). Breg production of IL-10 has been shown to inhibit T-cell 
proliferation and differentiation into Th1 and Th17 cells, and induce regulatory T-cell 
differentiation, thereby reducing the production and release of pro-inflammatory cytokines 
and repress the autoreactive responses (Flores-Borja et al., 2013).  
Furthermore, CD40-activated B cells have been found to be more efficient at inducing 
Foxp3+ regulatory T cells than other APCs; interaction between T cells and B cells being 
dependent on cellular contact via CD28 on T cells and CD86/CD80 on B cells (Chen and 
Jensen, 2007). In a study using EAE, researchers found that B cell deficiency results in 
delayed regulatory T cell response in the CNS, and that reconstitution with wild-type B cells 
restores the expression of IL-10 and Foxp3, whereas CD86/CD80 deficient B cells do not 
(Mann et al., 2007). It has been suggested that regulatory T cells can be induced by the 
interaction with CD40-activated naïve B cells via CD80 and CD86 (Mauri, 2010; Lemoine et 
al., 2011). These findings suggested that the interaction between B cells and T cells are 
highly dependent on these co-activation molecules.
 Chapter 3 General methodology 
3.1 Human subjects and sample collection 
In total 136 healthy volunteers were recruited from the Cambridge BioResource. The study 
was approved by the research ethic committee (15/SC/0087) and all subjects given valid 
written informed consent. 108 samples were first collected, with the date of attendance 
randomized regarding the genotypes at rs9282641, rs4810485 and rs1131265, the 
combination of which had been balanced by the Cambridge BioResource. Since the minor 
allele at rs9282641 has very low frequency among general population (5%), 28 homozygous 
subjects were recruited based on their genotype at rs9282641 and analysed as matched pairs 
(14 pairs). All data collection was undertaken fully blinded to genotype group. 50ml of 
peripheral venous blood was collected from each volunteer and was kept in EDTA- and 
lithium heparin- containing tubes for DNA genotype analysis and cell culturing respectively. 
5ml serum was collected in clotting activator serum tubes (S-Monovette, Sarstedt, Germany) 
and isolated by centrifugation for the first 108 subjects and stored at -80°C for batched 
ELISA analysis. All samples were collected in the morning and fully processed within four 
hours of collection. 
3.2 Mouse fibroblast cell line 
Mouse fibroblast L cells stably transfected with human CD40L (CD154) (kindly provided by 
Dr. D. Hodson) were grown in a humidified atmosphere containing 5% CO2 at 37°C in T25 
culture flasks. The medium used was Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Sigma-Aldrich, Life Science Ltd., St. Louis, USA) supplemented with 10% fetal bovine 
serum (FBS) and penicillin/streptomycin (p/s, 100 U/mL; 0.1 mg) (both from Sigma-
Aldrich). The efficacy of transfection was confirmed by mycoplasmid test, with the CD40L 
expression routinely checked by flow cytometry after staining with CD154-PE mAb. CD40L 
expressing and un-transfected control L cells were irradiated for 40 minutes (10,646 rads) 
prior to the co-culturing with PBMCs or B cells to prevent overgrowth. Repeated passaging 
of L cells using Trypsin/EDTA (ethylenediaminetetraacetic acid) (Sigma-Aldrich, Life 
Science Ltd., St. Louis, USA) was performed when the confluence of cells reached 90%. 
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3.3 PBMC isolation and activation 
Human peripheral blood mononuclear cells (PBMCs) were isolated freshly by Ficoll-Paque™ 
PLUS (GE Healthcare, Uppsala, Sweden) density gradient centrifugation. Blood collected in 
lithium heparin tubes were transferred in a sterile vessel and diluted with phosphate buffer 
saline (PBS) (1:1 dilution). 15ml of Ficoll medium was pipetted in 50ml falcon tubes. The 
diluted blood was carefully layered over the Ficoll medium to obtain a clear separation 
between the two. The falcon tubes were centrifuged at 300 x g for 30 min at 4℃ with 
maximum acceleration and the break function switched off. The PBMC layer located at the 
Ficoll-serum interphase was aspirated under visual control and transferred into a new 50ml 
falcon using a 10ml sterile plastic pipet. PBMCs were washed twice with PBS (centrifuged at 
350 x g for 10 min) before being counted.  
Isolated PBMCs were divided for ex vivo and in vitro flow cytometry analysis. For the in 
vitro analysis, all cells were cultured in RPMI-1640 (Sigma-Aldrich) medium supplemented 
with L-Glutamine (2 mM), p/s (100 U/mL; 0.1 mg) and 10% FBS (Sigma-Aldrich). PBMCs 
were mixed with irradiated CD40L-transfected/un-transfected L cells at a ratio of 20:1, and 
were cultured in 96-well U-bottom plates (1x106 PBMCs/well) for 72 h in a humidified 
atmosphere containing 5% CO2 at 37°C.  
For the paired samples, 4x106 freshly isolated PBMCs from both individuals were plated in 
U-bottom 96-well plate at 2x106 per well, with each well containing 150ul of the above 
mentioned RPMI medium, supplemented with Cell Stimulation Cocktail (phorbol 12-
myristate 13-acetate (PMA) and ionomycin cocktail, 2ul/ml, eBioscience Thermo Fisher 
Scientific), and Protein Transport Inhibitor Cocktail (Brefeldin A and Monensin cocktail, 
2ul/ml, eBioscience Thermo Fisher Scientific) to assess intracellular staining, and incubated 
for 5 h at 37°C prior to the staining. 
3.4 B/T cell separation and activation 
The rest of the PBMCs from the paired samples were stained with the separation panel for 30 
minutes, washed with sterile PBS and kept in 5ml Polypropylene tubes on ice till being 
sorted. The panel includes CD25-PE (Miltenyi Biotec), CD14-APC, CD45RA-BV786 (BD 
Biosciences), CD45RO-PerCP-Cy5.5, CD3-APC-Cy7, CD4-BV650 (all from BioLegend) 
and CD19-eFluor450 (eBioscience Thermo Fisher Scientific), as summarised in Table 3.4. 
CD19+CD14- B cells and CD3+ CD4+CD25-CD45RA+CD45RO- naïve T cells were sorted 
using BD Influx cell sorter, with confirmed purities of >99%. 
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Antibodies Fluorochromes Clone Company  Catalogue No. 
CD14 APC 61D3 ThermoFisher 17-0149-42 
CD4 BV650 RPA-T4 biolegend 300536 
CD19 eFluor450 HIB19 ThermoFisher 48-0199-42 
CD45RO PerCP-Cy5.5 UCHL1 biolegend 304222 
CD45RA  BV786 5H9 BD 563870 
CD3 APC-Cy7 SK7 biolegend 300318 
CD25 PE "4E3" miltenyi 130-091-024 
Table 3.4. The panel for isolating B cells and naïve T cells. 
CellTrace™ Far Red and CFSE cell proliferation kits (Thermo Fisher Scientific) were used, 
as per the manufacturer’s protocol, to quantify naïve T cell and B cell proliferation 
respectively. Briefly, isolated naïve T cells and B cells were diluted in pre-warmed serum-
free RPMI medium at 1x106 cells/ml with 1 mM CFSE slowly added into the B cell 
suspension and 1 mM Far Red into the T cell suspension. Cells were then incubated at 37 ̊C 
in a water bath for 20 min, washed twice with RPMI medium containing FBS. T cells were 
plated in the anti-CD3 (UCHT1, 1 mg/ml; eBioscience Thermo Fisher Scientific) –bounded 
U-bottom 96-well plates at 1x105 cells per well.  
Reagents used to activate B cells included soluble goat anti-human BCR F(ab’)2 fragment Ab 
(10 mg/ml; Jackson ImmunoResearch Laboratories) and IL-4 (20 ng/ml; R&D Systems), in 
addition to the CD40L-transfected L cells as described previously. B cells were co-cultured 
with L cells at the ratio of 15:1 in the U-bottom 96-well plates for 24h and were then added to 
T cell plate in at 2x105 cells per well in a total volume of 200 ml of medium and cultured for 
another 11 d. To measure the cytokine production profiles of B and T cells under ex vivo and 
in vitro conditions, cells were stimulated with Cell Stimulation and Protein Transport 
Inhibitor Cocktail 5 hours prior to cell surface and intracellular staining, which activated 
cytokine production and enabled the accumulation of cytokines within cells for detection by 
flow cytometry.  
3.5 Flow cytometry immunophenotyping 
Flow cytometry phenotyping of B cell and T cell subsets and their intracellular cytokine 
staining, besides B/T cell proliferation as mentioned above, was accomplished with 
antibodies targeting CD3 (APC-Cy7; BV570), CD4 (BV650), CD24 (PerCP), CD86 
(BV650), CD40 (BV605), IL-10 (PE-Dazzle 594), GM-CSF (PE-Dazzle 594), TNF-a 
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(AF700) (all from BioLegend); CD19 (eFluor 450), CD27 (PE-Cy7), IgD (FITC), CD38 
(APC), CD80 (PE) (all from eBioscience Thermo Fisher Scientific); IL-10 (BV786), IL-6 
(APC), IFN-y (BUV395), IL-17 (PE), CD25 (BUV737) (all from BD Biosciences). The 
purchase information of the panels used for phenotyping B cells in cultured PBMCs (Table 
3.5.1), and phenotyping B cells (Table 3.5.2) and T cells (Table 3.5.3) in co-culture 
experiments are as summarised below. 
Antibodies Fluorochromes Clone Company  Catalogue No. 
Viability dye eFluor506 NA ThermoFisher 65-0866-18 
CD3 APC-Cy7 SK7 biolegend 300318 
CD19 eFluor450 HIB19 ThermoFisher 48-0199-42 
CD27 PE-Cy7 O323 ThermoFisher 25-0279-42 
IgD FITC IA6-2 ThermoFisher 11-4724-42 
CD38 BUV395 HB7 BD 563811 
CD24 PerCP SN3 A5-2H10 ThermoFisher 46-0247-42 
CD86 BV650 FUN-1 biolegend 305428 
CD80 PE 2D10.4 ThermoFisher 12-0809-42 
CD40 BV605 5C3 biolegend 334336 
Table 3.5.1. The panel for phenotyping B cells in cultured PBMCs. 
Antibodies Fluorochromes Clone Company  Catalogue No. 
CFSE FITC NA ThermoFisher C34554 
Viability dye eFluor506 NA ThermoFisher 65-0866-18 
CD3 BV570 SK7 biolegend 300436 
CD19 eFluor450 HIB19 ThermoFisher 48-0199-42 
CD27 PE-Cy7 O323 ThermoFisher 25-0279-42 
CD86 BV650 FUN-1 biolegend 305428 
CD80 PE 2D10.4 ThermoFisher 12-0809-42 
CD40 BV605 5C3 biolegend 334336 
IL-10  BV786 JES3-9D7 BD 564049 
GM-CSF PE-Dazzle 594 BVD2-21C11  biolegend 502318 
IL-6  APC MQ2-13A5 BD 561441 
TNF-a AF700 MAb11 biolegend 502928 
CD25 BUV737 2A3 BD 564385 
CD38 BUV395 HB7 BD 563811 
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Table 3.5.2. The panel for phenotyping B cells in co-culture experiments. 
Antibodies Fluorochromes Clone Company  Catalogue No. 
Cell trace violet APC NA ThermoFisher C34572 
Viability dye efluor506 NA ThermoFisher 65-0866-18 
CD3 BV570 SK7 biolegend 300436 
CD4 BV650 RPA-T4 biolegend 300536 
IL-10 PE-Dazzle 594 JES3-9D7 biolegend 501426 
IFN-y  BUV395 B27 BD 563563 
IL-17 PE SCPL1362 BD 560436 
Table 3.5.3. The panel for phenotyping T cells in co-culture experiments. 
For general staining procedures, cells were first stained with Live/Dead marker Fixable 
Viability Dye eFluor506 (eBioscience Thermo Fisher Scientific) for 30 min at 4 ̊C and 
washed with FACS buffer (PBS, 0.1% BSA), after which cells were incubated in FACS 
buffer containing 2% mouse serum for 10 minutes at 4 °C to block unspecific binding sites, 
and stained with surface Abs for 20 min. Cells were then fixed and permeabilized using 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience Thermo Fisher Scientific). 
Intracellular Abs were added and incubated for 30 min at room temperature. Samples were 
then washed and analysed by LSRFortessa (BD Biosciences) and the corresponding 
FACSdiva software.  
Flow Cytometry Compensation Beads (Thermo Fisher Scientific) were used to set up 
compensation for all flow analysis. Data was analysed using FlowJo (Tree Star Inc.). Of note, 
for APC, AF700, PE-Dazzle and BV786, no distinct positive populations could be captured 
when the above-mentioned beads were used, resulting in a failure of compensation 
calculation. Such issue might be due to the incompatibility of intracellular antibodies and the 
beads. Therefore, antibodies with identical fluorochromes but targeting cell surface molecules 
were tested and used for setting up compensation (IgD-FITC, CD45RA-AF700, CD38-APC, 
CD45RA-BV786 and CD25-PE-Dazzle594). Notably, CD25-PE-Dazzle594 antibody 
couldn’t attached to the BD™ CompBeads properly as the other three, thus the alternative 
OneComp eBeads™ Compensation Beads were used instead for this single-color control. 
However, for APC, AF700, PE-Dazzle and BV786, no distinct positive populations could be 
captured, resulting in a failure of compensation calculation. Such issue might be due to the 
incompatibility of intracellular antibodies and the beads. Therefore, antibodies with identical 
fluorochromes but targeting cell surface molecules were tested and used for setting up 
compensation (IgD-FITC, CD45RA-AF700, CD38-APC, CD45RA-BV786 and CD25-PE-
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Dazzle594). Notably, CD25-PE-Dazzle594 antibody couldn’t attached to the BD™ 
CompBeads properly as the other three, thus the alternative OneComp eBeads™ 
Compensation Beads were used instead for this single-color control. 
3.6 Culture supernatant collection and storage 
PBMC culture supernatant was collected after three/twelve days’ culture and stored at -80°C 
for batched ELISA analysis in the future. For the collection of the co-cultured cells’ 
supernatant, 50ml/well of the supernatant from each condition was carefully collected 
without disturbing cell pallets prior to adding the activation cocktail at the end of the twelve 
days’ culture, and stored at -80°C. 
3.7 DNA purification and genotyping of MS and CBR samples 
DNA previously extracted by Dr Fiddes from PBMCs using TRIzol® Reagent (Life 
Technologies) was purified with the QIAamp DNA micro kit following the manufacturer’s 
“Clean-up of Genomic DNA” protocol. Samples were first lysed in the presence of proteinase 
K and Buffer ATL. Buffer AL was then added to the lysate, which were transferred onto 
QIAamp MinElute columns. DNA was washed with Buffer AW1 and Buffer AW2, before 
being eluted from the column using Buffer AE.  
DNA of the newly recruited 136 CBR samples were extracted from blood collected in EDTA 
tubes following the DNA Extraction Protocol. Blood collected in EDTA tubes were 
transferred to 50ml falcon tubes and incubated with lysis buffer (MgCl2 0.005M, TrisHCL 
pH7.5 0.02M) for 15 min on ice. The tubes were centrifuged for 7 min (3800 rpm, 4℃) to 
remove lysed red blood cells, with the pallet washed using lysis buffer till the pellet turned 
white. 5ml SE buffer, 50ul of proteinase K (20mg/ml) and 500ul of SDS (10%) were added to 
the pellet with vortex, and incubated overnight at 37°C. Afterwards, 2ml 5M NaCl was added 
into the tubes, which were shaken vigorously until foamed. The tubes were centrifuged for 15 
min (5000 rpm, 4℃) twice, with the pellets discarded and supernatants transferred into 20ml 
falcon tubes. 100% ethanol was added into the tubes slowly, which were inverted several 
times until a tight string of DNA became visible. The tubes were then centrifuged for 15 min 
(5000 rpm, 4℃) and the supernatants were carefully poured off. The DNA pellets were 
washed with 70% ethanol (centrifuged for 10 min at 5000 rpm) and dried for two hours with 
the tubes turned upside down onto tissue. DNA was resuspended in 500ul sterile water, with 
the DNA purity checked and concentration quantified using a Nanodrop 1000.  
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Genotyping was completed using Taqman methodology according to the manufacturer’s 
standard protocol. For genotyping DNA samples dried on one optical 384-well plate, a master 
mix containing 10ul TaqMan genotyping assay, 840ul MilliQ and 850ul of Universal PCR 
master mix was prepared. 4ul of master mix was dispensed into each well of the 384-plate 
using a multichannel pipette, and the plate was sealed with an optical plate cover and spun 
briefly. PCR reaction was done on the ABI 7900 machine using the following cycling 
conditions: 10 min at 95℃; 40 cycles (15 sec at 95℃, 1 min at 60℃). 
3 SNPs were genotyped (Table 3.7) for the correlation with B cell surface expression of 
CD86, CD80 and CD40. Genotypes were determined via the Quantstudio 7K Flex System 
using predesigned genotyping assays (Thermo Scientific). To check for genotyping 
consistency, duplicates were included for each subject.  
SNP Assay ID SNP Location Disease Association Gene 
rs9282641 C__30239585_20 Chr.3: 122077921 MS Risk Allele (A) CD86 
rs1131265 C__440401_20 Chr.3: 119503609 MS Risk Allele (C) CD80 
rs4810485 C__1260190_10 Chr.20: 46119308 MS Risk Allele (T) CD40 
Table 3.7. Genotyping at rs4810485, rs9282641 and rs1131265 using Taqman technology 
3.8 Statistical analysis 
Student’s unpaired t test was used for statistical comparisons between two groups, and paired 
t test was used for comparisons between the 14 genotype-paired samples. One-way ANOVA 
was used for statistical comparisons among more than two groups. All statistical tests have 
been indicated in the figure legends. P value <0.05 was considered significant. 
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Chapter 4 B cell stimulation using PBMCs 
4.1 Introduction  
In his PhD my predecessor Dr Fiddes showed that the MS associated variant rs9282641 
influences the expression of the co-stimulatory molecule CD86 on ex-vivo B cells (Smets et 
al., 2018). In my PhD I wanted to expand this on this work by assessing the influence of 
genotype in the context of stimulation, considering a wider range of B cell sub-types and 
establishing whether these observed expression changes had any effects on T cell 
proliferation. In his work Dr Fiddes had also shown that a second MS associated variant 
(rs4810485) influenced the expression of another co-stimulatory molecule CD40 in ex vivo B 
cell. It therefore seemed logical to explore the potential of using CD40 activation as a means 
of stimulating B cells in my experiments; the association with rs4810485 also suggest that 
this might be an MS relevant pathway. To establish the stimulation method, I tested and 
confirm the efficacy of using CD40L-transfected L cells to activate B cells, and optimised 
culture duration. To evaluate the genotype dependent effects on activated/un-activated B cells 
in vitro, I collected PBMCs from 108 healthy volunteers (recruited via the Cambridge 
BioResource on the basis of genotype) and 20 MS patients (recruited from our local clinic 
without the benefit of prior genotyping). Cells were then cultured with transfected/non-
transfected cells for three days, and the impact of genotypes on CD86, CD80 and CD40 
expression was assessed 
4.2 Correlating the genotype at rs4810485 with CD40 expression 
In his PhD Dr Fiddes had measured CD40 expression in a range of B cell sub-types from a 
large number of people but had not genotyped all of these subjects for the MS associated 
variant rs4810485 (which lies within the CD40 gene on chromosome 20). I therefore began 
my efforts to expand on his work by completing this genotyping in the 156 healthy volunteers 
previously studied by Dr Fiddes where the rs4810485 genotype was missing. These healthy 
individuals had all been collected from the Cambridge BioResource, FAC sorted and had 
CD40 expression quantified in a range of B cell sub-types. Dr Fiddes had extracted DNA 
from all these subjects using Trizol® Reagent (Life Technologies) but had not cleaned these 
samples. I therefore first cleaned these samples using QIAamp DNA micro kit’s “Clean-up of 
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Genomic DNA” protocol. I then measured the concentration and purity of the DNA using the 
Nanodrop 1000 and normalised aliquots from each sample to a concentration of 1ng/ul. 
Genotyping was then completed using Taqman methodology with a predesigned genotyping 
assay supplied by Thermo ScientificTM. The genotype of each subject was determined via the 
Quantstudio 7K Flex software System. To confirm the genotyping consistency, duplicates 
were included for all subjects. 
Genotyping was successful in 149/156 study participants (>95%) with 100% concordance 
between duplicates. The genotype frequencies were 61.8%, 29.5% and 8.7% for the GG 
homozygotes, GT heterozygotes and TT homozygotes respectively; frequencies which are in 
accordance with those seen in the EUR population from the 1000 Genomes Project (Phase 3) 
(Auton et al., 2015). I then tested for association between rs4810485 and the expression of 
CD40 as measured by Dr Fiddes in each of the B cell sub-types he assessed and found 
statistically significant evidence that carrying the rs4810485 risk allele (T) reduces the 
surface expression of CD40 in B cells, replicating the previously reported finding (Smets et 
al., 2018). 
4.3 Flow cytometry panel defining different B cell subtypes 
In order to define transitional B cells and plasmablasts, as well as the class-switched memory, 
non-class-switched memory and naïve B cell subtypes studied by Dr Fiddes, I designed and 
optimised a flow cytometry panel. I included a Live/Dead Fixable Blue Dead Cell Stain in 
this panel in order to be able to exclude debris and dead cells, which frequently confound the 
phenotyping of cultured cells (Perfetto et al., 2010). The photomultiplier tube (PMT) voltage 
of each channel was optimized to minimize spill-over between different channels during 
compensation (Dr Natalia Savinykh guided me in these efforts) (Adan et al., 2017). The PMT 
voltage for each channel is as shown in Table 4.3. These voltages were established in 
preparatory experiments based on 4 samples in two experiments and were maintained 
constant throughout the study. I used a BDTM CompBeads set stained with the antibodies 
conjugated with their respective fluorochromes as single colour controls for setting up the 
compensation, and PBMCs were used for the unstained control and Live/dead staining 
control. 
Antibodies Fluorochromes Detector name in the base configuration Voltages 
IgD FITC  blue laser-530/30 442 
CD24 PerCP blue laser-695/40 630 
CD38  APC  red laser-670/14 650 
CD3 APC-Cy7 red laser-780/60 646 
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CD19  eFluor450  violet laser-450/50  472 
Viability dye  eFluor506  violet laser-525/50  497 
CD40  BV605  violet laser-605/12  600 
CD86  BV650  violet laser-655/8  610 
CD80  PE  yellow laser-582/15  600 
CD27  PE-Cy7  yellow laser-780/60  699 
Table 4.3. Flow panel used for defining different B cell subtypes and their expression of CD86, CD80 and 
CD40, with the conjugated fluorochromes and the voltages for their respective detectors as displayed.  
The gating strategies I used to define the different B cell subtypes are as illustrated in Figure 
4.3. Briefly, lymphocytes were defined in the forward scatter-area (FSC-A) versus side 
scatter-area (SSC-A) plot and were then further gated for single cells by the ratio of area to 
width in forward scatter. The amine-reactive Live/Dead Fixable Blue Dead Cell Stain was 
used to gate out dead cells. Live B cells were gated as CD19+CD3- cells. The customarily 
used IgD/CD27 plot classified peripheral blood B cells into naïve (IgD+CD27-), non-class-
switched memory (IgD+CD27-) and class-switched memory (IgD-CD27+). Transitional B cells 
were gated as CD24hiCD38hi, and plasmablast as CD24-CD38hi. The same gating strategies 
defining different cellular subtypes were applied to all samples. Of note, considerable 
decrease of the CD24 and CD38 expression was found after 3 days’ culture, which made it 
difficult to define distinct populations of transitional B cells and plasmablasts reliably after 
this duration of culturing.  
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Figure 4.3. Gating strategies for defining class-switched memory, non-class-switched memory, naïve, 
transitional B cells and plasmablasts. The images were taken from ex vivo PBMCs.   
4.4 Stimulation method development 
To establish the optimal way of using CD40 to stimulate B cells, I compared both soluble 
CD40L (1ug/ml; Enzo Life Science) (Li et al., 2017) and CD40L-transfected L cells (at a 
PBMC to L cell ratio of 20:1) (Duddy et al., 2007). In these experiments for each of two 
subjects I collected PBMCs and established three parallel cultures; the first supplemented 
with soluble CD40L, the second co-cultured with CD40L-transfected cells and the third 
cultured without any supplementation (negative controls). I then compared the expression of 
CD86 and CD80 after three days (Figure 4.4). In the negative control cultures there was only 
minimal expression of the activation markers after three days’ culture. In contrast, both 
soluble CD40L and CD40L-transfected cells substantially increased the expression of CD86 
and to a lesser extent CD80, the increase being greatest with transfected L cells. 
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Figure 4.4. The expression of CD86 and CD80 in B cells after 3 days’ culture. 2x106 PBMCs were either 
cultured alone, supplemented with soluble CD40L or co-cultured with CD40L-transfected L cells (n=2). 
Given the higher activation efficiency of CD40L-transfected cells and under the assumption 
that the stimulation provided by cell-cell interaction was likely more physiologically relevant, 
I decided to use transfected L cells to activate B cells in my studies. To minimize the 
potential confounding effects resulting from the activation produced by L cells via some 
other form of signalling, non-transfected L cells were used instead for comparison in the 
studies. Based on the results from all collected samples, the effects of L cells per se in 
activating B cells were minimal, as shown in the following sections. 
4.5 L cells irradiation test and CD40L expression confirmation 
To prevent fibroblasts overgrowth, L cells were irradiated for 40 minutes (10,646 rads) prior 
to the co-culture. The growth rate of irradiated and un-irradiated cells was compared after 
three days. Images were taken using a CX41 Olympus microscope. The growth of irradiated 
L cells was visually reduced compared with the negative control, which had the same initial 
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number of cells (Figure 4.5.1). In the co-culture experiments irradiated L cells were mixed 
with PBMCs at the ratio of 1:20 and cultured in RPMI medium for three days. 
 
Figure 4.5.1. Cell growth after three days in unirradiated mouse fibroblasts (A) and cells irradiated for 40 
minutes (B). Bars indicate 50um. 
I then evaluated the surface expression of CD40L in transfected and un-transfected L cells 
using flow cytometry, in order to confirm that the transfected cells did indeed express CD40. 
In these experiments cells were dissociated with Accutase solution prior to the staining, rather 
than separated using Trypsin, to avoid any possible enzymatic cleavage of CD40L. Cells 
were then stained with anti-CD154-PE (CD40L). Representative results are shown in Figure 
4.5.2. Cells were gated as single cell using the FSC-A and FSC-W plot. A notably increased 
percentage of CD40L+ cell was found in the transfected population, with 69.6% of these cells 
positive for CD40L compared with just 1.09% in the un-transfected cells; these experiments 
thereby confirming the reliable transfection of CD40L in to these L cells.  
 
Figure 4.5.2. The expression of CD154 (CD40L) in transfected and un-transfected L cells. Cells had been 
gated as single cell using FSC-A and FSC-W prior to gating CD40L positivity.  
A B
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4.6 Optimisation of culture duration  
To confirm whether the conventionally used 3 days’ co-culture of PBMCs with CD40L-
transfected L cells could sufficiently activate B cells, I undertook a time course experiment in 
which (in each of two individuals) I co-cultured PBMCs for 12h, 24h, 48h and 72h, and then 
measured the expression of CD86, CD80 and CD40 in naïve B cells. I used co-cultures with 
un-transfected L cells as negative controls (Figure 4.6). The results demonstrated that the 
surface expression of CD86 and CD80 reached their peak expression at 24h but decreased 
very little out to 72h. By contrast, in the unstimulated conditions, the positivity of these CD86 
and CD80 were markedly lower as compared with the stimulated cells; the positivity of CD40 
was over 95% at all time points in both conditions. 
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Figure 4.6. The expression of CD86, CD80 and CD40 on naïve B cells in co-cultures with stimulated (left 
column) and un-stimulated L cells (right column).  
The experiments showed that B cells were maximally activated by L cells after 24 hours of 
co-culture and that the expression of CD86 and CD80 remain relative stable for the following 
48 hours. These data suggest that the standard approach of co-culture for three days was 
reasonable. 
4.7 Different B cell subtypes displayed distinct phenotypes 
Next, I assessed the expression of CD86, CD80 and CD40 in each of different B cell 
subtypes, namely class-switched memory B cells, non-class-switched memory B cells, naïve 
B cells, transitional B cells and plasmablasts, as defined by the gating strategies described 
previously. To do this I collected and processed venous blood samples from 108 healthy 
individuals recruited from the Cambridge BioResource (see methods). The gates defining the 
positive populations were established using Fluorescence Minus One (FMO) controls for 
each marker, as illustrated in Figure 4.7.1. To reduce batch effects, gates were always set to 
ensure that the positive population in each FMO control was 0.5% of total events.  
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Figure 4.7.1.  Example of CD86, CD80 and CD40 positivity under ex vivo and in vitro conditions. Gating 
was set to give positivity in FMO control of 0.5%. 
In ex vivo condition, CD86 was expressed by 4.01±0.25 % of B cells, rising to12.81±0.63 % 
after un-activated culture and 45.74±1.59 % when co-culture with activated L cells. 
Similarly, CD80 went from 5.87±0.47 % in ex-vivo conditions to 14.05±0.84 % after culture 
and 22.6±1.30 % in co-culture with activated L cells. In contrast the expression of CD40 
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decreased modestly from 95.15±0.38 % in ex-vivo cells to 91.55±0.77 % after culture and 
91.81±0.70 % in co-culture with activated L cells (see Figure 4.7.2). 
 
Figure 4.7.2. Expression of CD86, CD80 and CD40 in ex vivo and cultured B cells (unstimulated and 
stimulated). Figure is based on data from 108 healthy subjects (see methods).  
The Ex vivo expression of these surface markers on the five B cell subtypes, namely class-
switched memory, non-class-switched memory, naïve, transitional B cells and plasmablasts, 
is shown in Figure 4.7.3A. In the ex vivo condition, cell expression of CD86 and CD80 was 
highest in class-switched memory B cells and plasmablasts (P<0.0001), while CD40 was 
lowest in the transitional B cells and plasmablasts (P<0.0001). Notable variation was found in 
plasmablasts’ expression of CD86, CD80 and CD40, with about half of the cells being CD86 
positive, one-fifth being CD80 positive and three quarters being CD40 positive on average.  
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Figure 4.7.3. Expression of CD86, CD80 and CD40 in B cell subtypes in ex vivo (A), unstimulated (B) 
and stimulated (C) cultures (n=108).  
For cultured cells, the observed changes are summarised in Table 4.7. Compared with ex vivo 
cells, except for plasmablasts, the unstimulated B cell subtypes demonstrated significantly 
higher expression of both CD86 and CD80. When stimulated by CD40, these four B cell 
subtypes further increased their expression of CD86 and CD80, except for the expression of 
CD80 in transitional B cells, the increase of which is not statistically significant. Notably, the 
greatest increase of CD86 in response to CD40 ligation was found in naïve and transitional B 
cells, whereas the greatest increase of CD80 was found in class-switched memory B cells and 
non-class-switched memory B cells. By contrast, a decrease of CD86 and CD80 expression 
was found in plasmasblasts when cultured for three days without stimulation, and only CD86 
increased significantly after stimulation. The expression of CD40 increased moderately in 
class-switched memory B cells and transitional B cells but decreased slightly in non-class-
switched memory B cells and naïve B cells after three days’ culture without stimulation. For 
CD40 no difference was found between unstimulated and stimulated conditions in any B cell 
subtypes. 
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 Class-
switched  
Non-class-
switched  
Naïve  Transitional Plasmablast 
CD86 
Unstimulated 
vs. Ex vivo  
20.30 ± 1.00 
**** 
9.59 ± 0.53 
**** 
5.35 ± 0.52 
**** 
12.93 ± 1.10 
**** 
-13.15 ± 3.00 
**** 
Stimulated vs. 
Unstimulated 
21.12 ± 1.60 
**** 
28.85 ± 1.91 
**** 
38.84 ± 1.79 
**** 
33.15 ± 1.97 
**** 
23.82 ± 2.65 
**** 
CD80 
Unstimulated 
vs. Ex vivo  
24.70 ± 1.94 
**** 
14.44 ± 1.33 
**** 
3.04 ± 0.54 
**** 
9.09 ± 0.91 
**** 
-9.04 ± 2.05 
*** 
Stimulated vs. 
Unstimulated 
19.39 ± 2.28 
**** 
21.96 ± 2.10 
**** 
8.76 ± 1.11 
**** 
2.30 ± 1.33 
ns 
1.47 ± 1.85 
ns 
CD40 
Unstimulated 
vs. Ex vivo  
2.72 ± 0.63 
**** 
-1.04 ± 0.35 
** 
-4.37 ± 0.83 
**** 
3.07 ± 1.22 
* 
-2.52 ± 3.12 
ns 
Stimulated vs. 
Unstimulated 
-1.0 ± 0.55 
ns 
0.25 ± 0.49 
ns 
1.48 ± 0.94 
ns 
-0.11 ± 0.90 
ns 
-1.54 ± 3.80 
ns 
Table 4.7. The changes of CD86, CD80 and CD40 expression in class-switched memory B cells, non-
class-switched memory B cells, naïve B cells, transitional B cells and plasmasblasts after three days’ 
culture. Comparison was made between unstimulated and ex vivo conditions, and between stimulated and 
unstimulated conditions. The mean and standard deviation of the difference is shown in the table. *p<0.05, 
**p<0.01, ****p<0.0001. 
In conclusion, I have shown that naïve B cells demonstrate the greatest response to culturing 
and CD40L stimulation. Whether the increased CD86 expression and/or decreased CD40 
expression in cultured conditions are associated with the previous findings using ex vivo cells 
which implied that the risk genotypes can increase the expression of CD86 and decreased the 
expression of CD40 respectively will be further analysed in the following sections. 
4.8 CD86, CD80 and CD40 expression at the individual cell level 
On inspecting Figure 4.7.3 I noticed that, across the different B cell subtypes and the different 
conditions, there seemed to be a degree of correlation between the expression of CD86 and 
CD80 and anticorrelation between CD86 and CD40. Given that each data point in these plots 
represents the proportion of positive cells of that subtype that are expressing the marker, I 
wondered whether the expression of these molecules occurred in the same or different 
individual cells. To explore this question, I compared the observed proportion of double 
positive cells with the expected proportion for each pair of surface molecules in each of the 
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three main cell subtypes; class-switched memory, non-class-switched memory and naïve B 
cells (the low numbers of transitional B cells and plasmablasts prevented such analysis in 
these groups).  
The figures below summarise the pairwise comparison among CD86, CD80 and CD40 in the 
three B cell subtypes in ex vivo (Figure 4.8.1), unstimulated (Figure 4.8.2) and stimulated 
(Figure 4.8.3) conditions. Given the low positivity of CD86 and CD80, especially cells at 
resting state, variation among subjects was notable. For CD86 with CD80, within each 
cellular subtype and in each condition, I found that the observed proportion of double 
positive cells is significantly higher than the expected proportion. For CD40 with CD86, and 
CD40 with CD80, the observed proportion of double positive cell is significantly higher than 
that expected under random assortment for each cell type and in each condition (except for ex 
vivo class-switched memory B cells where the reverse is seen). 
52 错误!使用“开始”选项卡将 Heading 1 应用于要在此处显示的文字。 
 
 
Figure 4.8.1. Pairwise comparison of the proportion of observed and expected double positive cells among 
CD86, CD80 and CD40 in class-switched memory B cells, non-class-switched memory B cells and naïve 
B cells under ex vivo condition. The comparison was made using paired t-test. **p<0.01, ***p<0.001, 
****p<0.0001. 
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Figure 4.8.2. Pairwise comparison of the proportion of observed and expected double positive cells among 
CD86, CD80 and CD40 in class-switched memory B cells, non-class-switched memory B cells and naïve 
B cells under unstimulated condition. The comparison was made using paired t-test. ****p<0.0001. 
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Figure 4.8.3. Pairwise comparison of the proportion of observed and expected double positive cells among 
CD86, CD80 and CD40 in class-switched memory B cells, non-class-switched memory B cells and naïve 
B cells under stimulated condition. The comparison was made using paired t-test. ****p<0.0001. 
4.9 Genotypic effects on B cell expression 
For each of the subjects I studied the Cambridge BioResource provided the genotype for 
three MS associated SNPs - rs9282641 (which maps close to CD86), rs4810485 (which maps 
within CD40) and rs1131265 (another MS-associated SNP reported by GWAS studies 
mapping close to CD80 (Sawcer et al., 2011)). Genotype counts are shown in Table 4.9.1.  
These data allowed me to test for the influence of genotype on B cell subtype surface 
expression.  
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SNPs rs9282641 rs4810485 rs1131265 
Genotypes AA AG GG GG GT TT CC CG GG 
No. of subjects 20 19 68 43 27 37 39 19 48 
Table 4.9.1. The genotype counts at rs9282641, rs4810485 and rs1131265 in the 108 healthy controls 
provided by the Cambridge BioResource (for each SNP genotype data was missing in one/two subjects; no 
subject had more than one missing genotype).  
rs9282641 
Despite our earlier work I found no statistically significant evidence for an influence of this 
SNP on the expression of CD86 in any of the ex-vivo B cell subtypes (Figure 4.9.1A, D, G, J, 
M). This failure to replicate is likely to be a consequence of the smaller sample size in this 
study (lower power) and the inevitable regression to the mean. In contrast, statistically 
significant effects of genotype, consistent with those we previously reported (Smets et al., 
2018), were found in cultured cells. Carrying the risk allele (G) leading to greater expression 
of CD86 in naïve, class-switched memory and non-class-switched memory B cell subtypes in 
both unstimulated and stimulated cells; these differences being statistically significant in all 
but the unstimulated class-switched memory B cells (Figure 4.9.1).  
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Figure 4.9.1.  Percentage of CD86+ cells according to rs9282641 genotype, in naïve B cells (A-C), class-
switched memory B cells (D-F) and non-class-switched memory B cells (G-I). For each cell type results 
are shown in ex vivo (left), unstimulated (centre) and stimulated (right) conditions. In each panel the risk 
allele G is plotted on the right. 
Considering medium fluorescence intensity (MFI) rather than the percentage of positivity 
revealed significant changes only in the stimulated cells (Figure 4.9.2). In line with the results 
obtained considering the percentage of positive cells, the MFI of CD86+ cells were higher in 
individuals with the GG genotype in the stimulated condition (Figure 4.9.2C, F, I). In the ex 
vivo (Figure 4.9.2A, D, G) and unstimulated (Figure 4.9.2B, E, H) conditions, we found no 
significant association with genotype. The consistency of results between MFI and positivity 
indicates reliability in the gating strategies used. 
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Figure 4.9.2. MFI in CD86+ cells according to rs9282641 genotype in naïve B cells (A-C), class-switched 
memory B cells (D-F) and non-class-switched memory B cells (G-I).  
Mean expression in each genotype groups are shown in Table 4.9.2 for percentage positivity 
and MFI. In the stimulated condition, for both the percentage positivity and MFI, the risk 
allele homozygotes (GG) is significantly higher than the heterozygous (AG) individuals in all 
three B cell subtypes, with naïve B cells having the most significant difference.  
 Ex vivo Unstimulated Stimulated 
AA AG GG AA AG GG AA AG GG 
Naïve B cells % 1.8 1.8 1.8 5.1 4.8 8.5 39.1 34.5 51.1 
SD 1.5 1.1 1.5 2.8 2.2 5.8 16.6 10.2 17.2 
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MFI 753 668 739 1005 904 1058 1753 1550 2092 
SD 189 76 144 260 186 299 645 293 681 
Class-
switched 
memory B 
cells 
% 11.7 11.2 10.3 27.6 30.1 32.3 49.5 46.0 54.6 
SD 9.6 4.6 4.7 5.9 7.6 9.0 12.3 11.1 14.2 
MFI 1051 1060 1330 1507 1409 1614 2288 1804 2448 
SD 384 379 539 524 264 473 1068 526 771 
Non-class-
switched 
memory B 
cells 
% 2.3 2.5 2.1 9.3 11.0 12.8 33.6 32.3 44.9 
SD 1.6 1.6 1.8 3.6 5.3 5.3 14.8 13.0 20.0 
MFI 798 702 838 1013 961 1124 1479 1500 2012 
SD 200 105 367 285 261 380 797 491 864 
Table 4.9.2. Genotype specific expression of CD86 positivity and MFI in naïve B cells, class-switched 
memory B cells and non-class-switched memory B cells in ex vivo, unstimulated and stimulated 
conditions.  
rs4810485 
Similarly, results concordant with those we observed previously (Smets et al., 2018) were 
seen for the effects of rs4810485 genotype on the expression of CD40. The risk allele reduces 
the expression with statistical significance in the majority of the cell types amongst the 
unstimulated and stimulated cells for both CD40 positivity and MFI. (Figure 4.9.3 and 4.9.4). 
Table 4.9.3 lists the mean expression level in each genotype group.  
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Figure 4.9.3. Positivity of CD40 according to rs4810485 genotype; in naïve B cells (A-C), class-switched 
memory B cells (D-F) and class-switched memory B cells (G-I) in ex vivo, For each cell type results are 
shown in ex vivo (left), unstimulated (centre) and stimulated (right) conditions. In each panel the risk allele 
T is plotted on the right. 
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Figure 4.9.4. MFI of CD40+ cells according to rs4810485 genotype; in naïve B cells (A-C), class-switched 
memory B cells (D-F) and class-switched memory B cells (G-I). The risk allele T is plotted on the right. 
 Ex vivo Unstimulated Stimulated 
GG GT TT GG GT TT GG GT TT 
Naïve B cells % 96.0 96.5 95.0 93.9 92.4 88.0 95.1 93.6 89.8 
SD 3.9 3.7 3.9 5.4 6.9 8.9 4.2 5.3 6.3 
MFI 4294 4209 3300 3372 2620 2522 5480 4742 3579 
SD 1701 1647 1036 2010 1213 1103 3029 2032 1427 
Class-
switched 
memory B 
cells 
% 94.3 95.5 93.1 98.0 96.4 96.0 96.6 96.3 94.7 
SD 7.0 3.2 4.2 2.0 4.0 4.1 4.1 3.6 4.8 
MFI 5253 5416 4667 5343 4676 4666 7361 6545 5567 
SD 1997 1986 1476 2260 1904 2053 4133 2254 2927 
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Non-class-
switched 
memory B 
cells 
% 97.8 98.2 97.8 97.7 97.1 95.7 98.3 96.6 96.0 
SD 2.4 1.7 2.0 2.2 2.2 3.8 2.1 5.8 4.0 
MFI 4160 4379 3697 4150 3530 3437 7888 6549 5189 
SD 1572 1700 1068 2237 1250 1511 4507 2526 2526 
Table 4.9.3. Genotype specific expression of CD40 positivity and MFI in naïve B cells, class-switched 
memory B cells and non-class-switched memory B cells in ex vivo, unstimulated and stimulated 
conditions.  
 
rs1131265 
I found no significant association between CD80 expression and the genotype at rs1131265 
(Figure 4.9.5), suggesting that the effects of rs1131265 on MS risk are unlikely to be related 
to any effect on CD80 expression. Although it is still possible that such an effect exists, it is 
too modest to be detectable with the number of subjects tested in this study. 
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Figure 4.9.5. CD86 expression in naïve, class-switched and non-class-switched B cells and according to 
rs9282641 genotype. 
The genotypic effects on the expression of CD86, CD80 and CD40 were tested in transitional 
B cells and plasmablasts, but no statistically significant effects were observed (Figure 4.9.6, 
4.9.7 and 4.9.8). The reduced number of cells in these two subtypes present after three days 
will undoubtedly have limited the power to see effects in these sub-types. 
The genotypic effects of these three SNPs on the composition of B cell subtypes were also 
analysed. Although remarkable variation in the relative proportions of B cell sub-types 
existed between individuals, no significant result was found suggesting that any of these three 
SNPs affect the relative proportions of the different cell types. In this context it therefore 
seems unlikely that the genotypic effects we observed in naïve B cells have resulted from 
changes in the percentage of CD24hiCD38hi or CD24-CD38hi subpopulation, although these B 
cell subtypes displayed markedly different phenotypes in terms of CD86, CD80 and CD40 
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expression. Whether the variation in B cell composition is dependent on other un-typed MS 
associated SNPs that affect B cell development and maturation was not addressed in this 
study. 
 
Figure 4.9.6. CD86 expression in transitional B cells and plasmablasts according to rs9282641 genotype. 
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Figure 4.9.7. CD40 expression in transitional B cells and plasmablasts according to rs4810485 genotype. 
 
Figure 4.9.8. CD80 expression in transitional B cells and plasmablasts according to rs1131265 genotype. 
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4.10 Comparison between MS and healthy subjects 
In an effort to explore the genotypic effects found in healthy controls in the context of 
disease, I also collected PBMCs from 20 MS patients (excluding those taking fingolimod or 
other B cell depletion therapy). Unfortunately, the low frequency of the minor alleles for the 
SNPs of interest in the European population, together with the modest number of patient 
available for study meant that the majority of patients I studies (18/20) where in fact 
homozygotes for the major allele (GG), the other two subjects being heterozygotes (AG) and 
none of the subjects being homozygous for the other allele. The low numbers of patients with 
other genotypes limited the power to look for genotype effects within patients. I found no 
case control difference in the positivity of CD86, CD80 and CD40 in total B cells (Figure 
4.10) - even when data was restricted to just those cases and controls that were homozygous 
for the common allele (GG). 
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Figure 4.10. The positivity of CD86, CD80 and CD40 in total B cells from healthy controls and MS 
patients in ex vivo and in vitro conditions.  
4.11 Summaries and conclusions 
By studying PBMCs from 108 healthy volunteers selected on the basis of genotype (to ensure 
adequate representation of each possible genotype), I have shown that, across various B cell 
developmental stages (i.e. transitional, naïve, non-class-switched, class-switched B cells and 
plasmablasts), the expression of CD86, CD80 and CD40 varies considerably in ex vivo 
condition. I also shown that the response of B cells to stimulation via CD40 differ markedly 
between these subtypes, with naïve B cells, transitional B cells and plasmablasts more readily 
increasing CD86 positivity, and non-class-switched and class-switched memory B cells 
tending to enhance CD80 positivity preferentially. Interestingly using a single cell approach, I 
was also able to show that within B cells CD86 expression is positively correlated with the 
expression of CD80, a coupling that was strongest in ex vivo naïve B cells.  
Although I was unable to replicate the established association of rs9282641 and rs4810485 
genotype on the expression of CD86 and CD40 respectively in the ex-vivo cells from my 
study subjects, which is almost certainly due to the limited power in this study, I was able to 
confirm effects concordant with those we described previously (Smets et al., 2018) in many 
of the B cell subtypes after culture; the effects of rs9282641 and rs4810485 genotype being 
strongest in CD40 activated naïve B cells. The scale of changes in expression resulting from 
carrying MS risk alleles were substantially larger in the cultured cells, particularly after 
stimulation. As in the ex-vivo cell analysis the absence of statistically significant genotypic 
effects in the transitional B cells and plasmablasts most likely relates to limitations of power. 
Comparisons between MS and controls samples revealed no major difference suggesting that 
the effects of these SNPs observed in the healthy subjects I studied are likely to also apply in 
the context of disease.  
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Chapter 5 T/B cells co-culture 
5.1 Introduction  
Having demonstrated that the effects of the MS associated genotypes on CD86 and CD40 
expression are amplified in B cells that are first activated by CD40L, I hypothesized that one 
consequence of this increased expression might be an increased proliferation and perhaps 
proinflammatory differentiation of T cells. Since PBMCs contain a variety of cell types and 
cellular subtypes, and the relative proportion of B cells and T cells varies between 
individuals, I reasoned that to test this hypothesis, it would be more informative to explore 
this question by combining purified B cells and purified naïve T cells and then co-culturing 
these in isolation from other cell types. In addition, I wanted to further elucidate the potential 
underlying molecular mechanisms that might drive any effect on T cells that resulted from 
changes in B cell expression. The available literature suggests several relevant intracellular 
cytokines could be involved (Duddy et al., 2007; Barr et al., 2012; Li et al., 2015), which I 
therefore wanted to include in a new extended panel. To undertake an evaluation of these 
hypotheses I collected PBMCs from 28 healthy subjects (recruited via the Cambridge 
BioResource on the basis of genotype) and 13 MS patents (recruited from our local clinic 
without the benefit of prior genotyping). From each sample I separated B cells and naïve T 
cells and labelled these with CellTrace™ CFSE, and CellTrace™ Violet respectively. I then 
set up parallel one-day cultures of the B cells, the first with CD40L transfected L cells and 
the second with un-transfected L cells. In parallel I set up three T cell cultures all in plates 
with bound CD3. After the initial one-day B cell activation phase, I then co-culture each set 
of B cells with the naïve T cells from the same individual for 11 days; the third T cell culture 
had no added B cells. All these cultures were supplemented with IL-4 and goat anti-human 
IgM BCR cross-linking antibody. At the end of the 12th day from each individual I therefore 
had one T cell and activated B cell co-culture, one T cell and un-activated B cell culture and 
one T cell alone culture. Within the context of each individual I was therefore able to assess 
the impact of the increased expression of the co-stimulatory molecules (CD80 and CD86) 
induced by activation of CD40. While comparison between individuals enabled me to assess 
the impact of genotype and disease state in each of the conditions.  
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5.2 Optimising the voltages for B/T cell panels 
In the context of the fluorochrome-conjugated antibodies that were already available to me, to 
avoid compromising flow cytometer’s compensation capacity, I would need to define and 
optimise two separate panels: one panel focusing on B cell phenotypes and the other on T cell 
phenotypes. In addition to viability dyes, I also used CellTrace CFSE/Violet in the 
proliferation assay. Ultimately the B cell panel included 8 surface and 4 intracellular makers, 
whereas the T cell panel had 3 surface and 3 intracellular markers. With the kind assistance 
from Dr. Mukanthu Nyirenda, I optimised the voltages for each channel to minimize the 
compensation parameters. Table 5.2.1 and 5.2.2 summarize the target molecules, the 
conjugated fluorochrome, the laser detectors and the finalized voltage values in both panels.  
Antibodies Fluorochromes Detector name in the base 
configuration 
Voltages 
Proliferation assay CellTrace™ CFSE  blue laser-530/30 445 
IL-6  APC  red laser-670/14  540 
TNF-α  AF700  red laser-735/45  520 
CD19  BV450  violet laser-450/50  429 
L/D  BV506  violet laser-525/50  496 
CD3  BV570  violet laser-585/15  520 
CD40  BV605  violet laser-605/12  520 
CD86  BV650  violet laser-655/8  600 
IL-10  BV786  violet laser-780/60  561 
CD80  PE  yellow laser-582/15  579 
GM-CSF  PE-Dazzle 594  yellow laser-610/20  510 
CD27  PE-Cy7  yellow laser-780/60  550 
CD38  BUV395  UV laser-379/20  371 
CD25  BUV737  UV laser-740/35  650 
Table 5.2.1. B cell panel showing fluorochrome and voltages. 
Antibodies Fluorochromes Detector name in the base 
configuration 
Voltages 
Proliferation assay CellTrace™ Violet  red laser-670/14  540 
CD19  BV450  violet laser-450/50  429 
L/D  BV506  violet laser-525/50  496 
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CD3  BV570  violet laser-585/15  520 
CD4  BV650  violet laser-655/8  600 
IL-17  PE  yellow laser-582/15  579 
IL-10  PE-Dazzle 594  yellow laser-610/20  510 
IFN-γ  BUV395  UV laser-379/20  371 
Table 5.2.2. T cell panel showing fluorochrome and voltages  
5.3 Establishing the baseline state of surface and intracellular 
markers in ex vivo cells 
Figure 5.3.1 demonstrates the gating strategies from B cell and T cell panel, which allow for 
characterizing CD4+ T cell, memory B cell and naïve B cell populations. After 5 hours’ 
culture with PMA/ionomycin and GolgiStop, the morphology of cells, their viability and 
percentage of various cellular subtypes remained largely the same as the freshly isolated 
PBMCs described in the previous chapter.  
 
Figure 5.3.1. Gating strategies for defining CD4+ T cell, memory B cell and naïve B cell populations. 
Freshly isolated PBMCs were activated with PMA/ionomycin and GolgiStop mix for five hours before 
being analysed by flow cytometry.  
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This experiment was based on 4x106 PBMCs from each of the 28 healthy CBR subjects and 
13 MS. First, the expression of CD86, CD80, CD40 and CD25 was compared between 
memory and naïve B cells (see Figure 5.3.2 and Table 5.3). In accordance with the results 
using ex vivo cells, the expression of CD86 and CD80 by naïve B cells was minimal and was 
significantly lower than memory B cells. CD40 and CD25 positivity was also lower in naïve 
B cells than in memory B cells. Similarly, the expression of the four intracellular markers 
was also significantly lower in the naive population than in the memory population. 
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Figure 5.3.2. Positivity of surface (CD86, CD80, CD40 and CD25) and intracellular (IL-6, IL-10, GM-
CSF ad TNF-α) markers in memory and naïve B cells. Cells were activated with PMA/ionomycin and 
GolgiStop mix for 5 hours before staining fixation. Memory B cells had significantly higher expression of 
these markers than naïve population. ****p<0.0001. 
 Memory B cells Naïve B cells Mean of 
differences 
SD of differences 
CD86 9.05 5.56 3.49 1.94 
CD80 15.91 1.10 14.81 6.76 
CD40 96.87 93.18 3.69 4.17 
CD25 37.33 8.13 29.19 11.32 
IL-6 3.15 1.09 2.06 1.89 
IL-10 9.19 2.99 6.20 3.14 
GM-CSF 7.44 4.19 3.25 2.82 
TNF-α 51.63 24.08 27.55 10.84 
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Table 5.3. Mean and SD of differences between memory and naïve B cells’ expression of CD86, CD80, 
CD40, CD25, IL-6, IL-10, GM-CSF and TNF-α. 
Next, I compared the expression of these markers between CD25+ and CD25- B cells (Figure 
5.3.3). Like CD27+ memory B cells, cells that are CD25 positive had significantly higher 
expression of the surface and intracellular makers. In general, the phenotypes of CD25+ B 
cells overlapped with those of memory B cells.  
 
Figure 5.3.3. Positivity of surface (CD86, CD80, CD40) and intracellular (IL-6, IL-10, GM-CSF ad TNF-
α) markers in CD25+ and CD25- B cells. **p<0.01, ***p<0.001, ****p<0.0001. 
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5.4 B cells and naïve T cells isolation 
In the previous chapter, PBMCs were cultured with L cells for three days. However, in order 
to avoid any confounding influence on the interaction between B cells and T cells attributable 
to other cell types included within PBMCs, I only included T and B cell in these second 
round of experiments. For example, since co-stimulatory molecules such as CD86 and CD40 
are also expressed on monocytes, it would be impossible to infer that any difference seen in T 
cell responses had resulted from genotypic effects on B cells, unless monocytes had been 
excluded from the co-culture. Thus, to test for effects on T cells resulting from changes in B 
cells during co-culture, I wanted to use a cell sorting strategy to isolate B cells and naïve 
helper T cells (Th0) with high purity, so that I could combined only these cells in these 
experiments. This more restricted co-culture also allowed me to set the relative proportion of 
T and B cells based on existing literature (Li et al., 2017). 
I initially tested the suitability of the Human B Cell and naïve CD4+ T Cell Isolation Kits 
available from Miltenyi Biotec. Processing the samples using these kits manually in a hood 
(to reduce the risk of contamination) gave high levels of purity (>95%) but inadequate 
numbers of cells. Using the autoMACS Pro Separator available in the lab (which could only 
be operated in a non-sterile environment) improved the yield but gave inadequate levels of 
purity (<90%).  
I next tested the BD InfluxTM Cell Sorter available at NIHR BRC-Cambridge Phenotyping 
Hub. According to the regulations of the facility, the Influx machine needs to be operated by 
their own specialized staff. Therefore, after I have finished isolating and staining the PBMCs 
with the designed separation panel, the operation of the machine was performed by the staff 
at the facility. Figure 5.4 illustrates the gating strategies used for isolating B cells (CD3-
CD19+CD14-) and naïve T cells (CD3+CD19-CD4+CD45RO-CD25-CD45RA+). Briefly, B cell 
and T cell populations were defined using the standard CD3 and CD19 makers, with B cells 
further gated to be CD14- to exclude any CD19+ monocytes. Since CD4+ responder T cell 
population is expected to have both naïve and memory T cells, CD45RO and CD45RA were 
used to exclude memory responder T cells, and CD25+ regulatory T cells were also excluded 
from the naïve population. An example of the purities routinely checked by flow cytometry 
for B cells and naïve T cells are shown in the figure. 
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Figure 5.4. Sorting strategies to isolate B cells and naïve T cells from PBMCs. Typical purities are 
shown in the panel.  
5.5 Minimizing gating strategy bias 
Samples were provided by the Cambridge BioResource in pairs, one sample from a risk allele 
homozygote and one from a wild type allele homozygote (I was blind to the genotypes until 
all samples had been processed and the data finalised). In Chapter 4, in order to maintain the 
consistency of gating strategies across all samples that were processed, I used FMO controls 
for each of the three surface markers. However, given the larger number of makers being 
analysed simultaneously, it was technically and financially infeasible to set up individual 
FMO for all markers. I therefore used unstained control instead to help decide the positive 
populations for each marker. Since proliferating cells tend to have greater forward scatter 
(FSC) and side scatter (SSC) than the original un-proliferated population (which implies that 
these cells are larger in size and more granular) (Adan et al., 2017), I used the same gates for 
defining lymphocytes in each pair of samples; thereby avoiding the tendency for any 
confounding related to the changes in FSC/SSC induced by proliferation.  
In most cases, a distinct lymphocyte population separated from the cell debris could be easily 
identified, so that lymphocytes could be defined with confidence (Figure 5.5A). To test how 
the gate boundaries might affect the measurement of proliferation in these samples, the 
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boundary of the gate was set at six random position within the range of the two red lines 
shown in figure 5.5A. Adjusting the gate in the interval between the two lines only resulted in 
very modest, and highly correlated, changes in the percentage of proliferated cells in the two 
samples (Figure 5.5B), confirming the precise, and essentially arbitrary, positioning of the 
gate had little to no consequence on the comparison between the two samples. Across the 14 
pairs of samples, there were two pairs in which a clear boundary couldn’t be seen, as shown 
in Figure 5.5C. This was most likely due to the relatively lower number of cells acquired after 
12 days’ culture. In such cases, it is less convincing that the gating strategies for these two 
pairs can be as reliable as the other and were therefore excluded from the proliferation 
analysis. 
 
Figure 5.5. Example FSC-H/SSC-H plots used for defining lymphocytes (A and C). The right-hand plots 
show the relationship between the percentage of proliferating T cells in the two samples (X and Y axis) as 
the position of the gate is varied (B and D). 
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5.6 Surface and intracellular markers in co-cultured cells 
In order to be able to distinguish the T or B cell origin of the cells present after co-culture, B 
cells were labelled with CellTrace™ CFSE, and naïve T cells with CellTrace™ Violet. To 
establish the influence of pre-activation via CD40 I set up parallel one-day cultures of B cells, 
one with un-transfected L cells and the other with CD40L-transfected L cells. In my earlier 
time-course experiment (Figure 4.6) I showed that this duration of exposure is sufficient to 
boost B cells’ expression of the co-stimulatory molecules CD86 and CD80. After this first 
24-hour pre-activation, each set of B cells were then co-cultured with naïve T cells for a 
further 11 days. At day 12, each co-culture was subjected to a 5-hour activation with 
PMA/ionomycin and GolgiStop mix. The cellular proliferation together with the expression 
of costimulatory molecules and intracellular cytokines were then measured in both B and T 
cells (Figure 5.6.1).  
 
Figure 5.6.1. Gating strategies for in vitro cells after 12 days’ culture. Purified B cells were first activated 
by CD40L-transfected L cells for 1 day, and then co-cultured with naïve T cells for another 11 days.   
Due to the limited number of cells available for co-culture in some cases, I was unable to 
have the un-activated condition for 5 pairs of samples, ending up with 24 activated samples 
and 14 un-activated samples. As anticipated I saw significantly higher proliferation in the co-
culture where the B cells had been pre-activated by exposure to CD40L-transfected L cells 
than in those where the B cells had only been pre-exposed to un-transfected L cells 
Aqua
CD
3
CD19 CD4
错误!使用“开始”选项卡将 Heading 2 应用于要在此处显示的文字。 错误!
使用“开始”选项卡将 Heading 2 应用于要在此处显示的文字。 
77 
 
(p=0.0002) (Figure 5.6.2A). The CD40L pre-activated B cells had higher CD86 and CD25 
positivity, although this increase was not statistically significant (Figure 5.6.2B, E). Likewise, 
there was no statistically significant difference in the expression of CD40 itself on these B 
cells (Figure 5.6.2D). By contrast, CD80 expression was significantly higher on the activated 
B cells (p=0.0059) (Figure 5.6.2C). The positivity of TNF-αwas significantly lower in the 
activated cells (p=0.0077) (Figure 5.6.2F) but there was no difference in GM-CSF positivity 
(Figure 5.6.2H). In accordance with literature, B cells activated with CD40L had significantly 
lower expression of IL-10 (p<0.0001) (Figure 5.6.2G) and higher expression of IL-6 
(p=0.0057) (Figure 5.6.2I).  
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Figure 5.6.2. B cell proliferation and phenotypes after 12 days of co-culture with naïve T cells. Human B 
cells were labelled with CFSE and were either pre-activated with CD40L-transfected L cells, BCR and IL-
4, or un-transfected L cells, before co-culture with naïve T cells. **p<0.01, ***p<0.001, ****p<0.0001. 
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To analyse whether activated B cells can induce the proliferation of naïve T cell, T cells were 
cultured in CD3-plated wells for 12 days, either co-cultured with pre-activated B cells, un-
activated B cells or without B cells. Co-culturing un-activated B cells with T cells strongly 
promoted T cells proliferation (p<0.0001) (Figure 5.6.3A) and IFN-γ production (p=0.0018) 
(Figure 5.6.3B) as compared with culturing T cells alone. Compared with un-activated B cell, 
activated B cells further promoted T cell proliferation (p<0.0001) and IFN-γ production 
(p=0.034). Co-culturing B cells also increased IL-17 production, which didn’t seem to be 
dependent on activation with CD40L and BCR (Figure 5.6.3C).  By contrast, IL-10 positivity 
in T cells was significantly lower when co-cultured with activated B cells (p=0.0002), and 
co-culturing un-activated B cells didn’t affect IL-10 production as compared with culturing T 
cells alone (Figure 5.6.3D).  
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Figure 5.6.3. T cell proliferation and phenotypes after 12 days’ culture. Human T cells were labelled with 
CellTrace Violet and were either co-cultured with activated B cells and un-activated B cells or cultured 
without B cells. Proliferation (A), IFN-γ (B), IL-17 (C) and IL-10 (D) expression. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
Although CD86 is predominantly expressed on APCs, I also found that within the T cell 
population there is a distinct CD86 positive sub-population (Figure 5.6.4A). Compared with 
T cells co-cultured with pre-activated B cells, T cells cultured with un-activated B cells 
displayed significantly higher percentage of CD86 positive cells (p=0.0006); in contrast to 
the findings in B cells. T cells also displayed modest positivity of CD40 and CD80 (Figure 
5.5.4B and C), with CD80 significantly higher (p=0.0018) and CD40 (p<0.0001) 
significantly lower in the activated condition. Although CD25+ T cells had been excluded 
from the naïve T cell population, after 12 days’ co-culture with B cells, a proportion of T 
cells were once again CD25+, with no statistical difference between the two experimental 
conditions (Figure 5.6.4D). By contrast, in the activated condition, the positivity of GM-CSF 
was significantly higher in the activated condition (p=0.0003) (Figure 5.6.4E). Although 
considerable number of T cells were TNF-α positive, activating B cells did not result in any 
difference between the two (Figure 5.6.4F).  
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Figure 5.6.4. T cell phenotype after 12 days’ culture. CD86 (A), CD80 (B), CD40 (C), CD25 (D), GM-
CSF (E) and TNF-α(F) expression. **p<0.01, ***p<0.001, ****p<0.0001 
5.7 Genotypic effects on B cells and T cells 
Having demonstrated that co-culturing with B cells results in proliferation of the T cells, and 
that this proliferation is increased when B cells have been pre-activated via CD40, I went on 
to assess the effects of genotype on the observed changes. Once again, the Cambridge 
Bioresource (CBR) provided the genotype for all three of the SNPs of interest. These 
genotypes were only provided after all sample collection and processing was complete, so 
that I was blind to the genotype during the experiments. Samples were provided by CBR in 
pairs based on their genotype (one major allele homozygote and one minor allele 
homozygote) to reduce any confounding related to batch effects. Given the low minor allele 
frequency of rs9282641, this massively increased the efficiency of the experiment compared 
to random recruitment. Ultimately CBR provided 14 pairs samples (28 individuals). As 
expected, in such a modest number I saw no significant association of genotype with CD86 
positivity in the ex vivo cells B cells, B cell subtypes or T cells (Figure 5.7.1A). In the 
activated condition (Figure 5.7.1B), however, the proliferation of T cells was significantly 
higher in individuals carrying GG risk allele (p=0.0125). No statistically significant 
difference was found in B cell proliferation or CD86 expression by B/T cells. There were no 
statistically significance associations with genotype in the un-activated condition (Figure 
5.7.1C). As noted in Chapter 5.5, in 2 pairs of the samples there were insufficient cells 
available after co-culture, hence the total number of samples included in the activation 
analysis was reduced to 24 (12 pairs). 
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Figure 5.7.1. Genotype specific expression of CD86. Row A demonstrates the positivity of CD86 in ex 
vivo total B cells, memory B cells, naïve B cells and T cells. Row B and C show after 12 days’ co-culture 
the proliferation of T cells and B cells and their CD86 positivity in activated and un-activated in vitro 
conditions. *p<0.05.  
Although not statistically significant, the expression of CD86 was higher in risk allele 
homozygotes as expected. The modest sample size employed in this complex, time 
consuming and costly follow up experiment has limited power, and it is clear that more 
samples would need to be assessed to confirm the results suggested here, i.e. that the 
increased expression of CD86 on B cells resulting from carrying the risk allele at rs9282641 
leads to increased proliferation of T cells, particularly in the context of immune stimulation.  
In addition, I also looked for association with rs4810485 (the CD40 related SNP) and 
rs2293370 (the CD80 related SNP). Data from a different CD80 related SNP was provided by 
the Cambridge BioResource as they had not genotyped rs1131265 in many of their samples. 
Recruits were therefore selected on the basis of rs2293370 genotype; this SNP being a perfect 
proxy for rs1131265 (the two SNPs having a D’ and r2 of 1.0). A summary of the genotypic 
information is shown in Table 5.7.  
SNPs rs4810485 rs2293370 
Genotypes GG GT TT AA AG GG 
No. of subjects 14 11 3 1 10 17 
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Table 5.7. The genotype information at rs4810485 and rs2293370 (risk allele: G) for the 28 healthy 
controls was collected from Cambridge BioResource.  
No statistically significant associations were seen with either rs4810485 or rs2293370. Again, 
the modest sample size of this experiment limits its power, even to detect the previously 
confirmed associations. Given the previous suggestion that the genotype at rs4810485 might 
influence the downstream expression of IL-10 (Smet et al., 2018), the positivity of IL-10 was 
also examined. In Figure 5.7.2A ex vivo CD40 positivity was compared between genotypes 
in B cells, in particular the memory and naïve subtypes. Individuals carrying homozygous 
risk allele (TT genotype) demonstrated slightly lower IL-10 positivity in B cells. After 12 
days’ culture, both activated and un-activated B cells showed decreased CD40 positivity, 
from over 95% in ex vivo cells to around 60% (Figure 5.7.2B). The carriage of the risk allele 
T in the heterozygous state also seemed to be associated with a trend of decreased CD40 and 
IL-10 positivity. These findings are thus in accordance with our previous data suggesting that 
CD40 expression and the plasma levels of IL-10 correlated with the CD40 SNP in untreated 
MS patients (Smets et al., 2018). If I had had sufficient time I would like to have measured 
the level of IL-10 in culture supernatant and tested this for association with genotype.  
 
Figure 5.7.2. Expression of CD40 and IL-10 by genotypes at rs4810485. Row A demonstrates the 
positivity of CD40 in ex vivo total B cells, memory B cells, naïve B cells, and IL-10 in total B cells 
(n=28). Row B CD40 expression after 12 days’ co-culture. Row C IL-10 positivity in activated (n=28) and 
un-activated (n=14) in vitro conditions.  
The expression of CD80 was compared between different genotypes at rs2293370 (Figure 
5.7.3), however, with only one AA homozygous individual available among the 28 subjects 
this analysis was primarily a comparison between heterozygotes and risk allele homozygotes. 
Similar to the results from the 3 days’ culture, no statistically significant association between 
CD80 expression and genotype was observed.  
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Figure 5.7.3. Expression of CD80 by genotypes at rs2293370. Row A demonstrates the positivity of CD80 
in ex vivo total B cells, memory B cells, naïve B cells (n=28), and Row B demonstrates after 12 days’ co-
culture the positivity of CD80 in activated (n=14) and un-activated conditions. 
5.8 Comparison between proliferated and un-proliferated cells 
To assess the impact of the proliferation induced by the initial activation for 24 hours via 
CD40 on the eventual phenotype of the B cells after 12 days of culture, I compared the 
expression of the four surface makers and four intracellular markers between the proliferated 
and non-proliferated B cells in the activated cultures (Figure 5.8.1). The B cells that had 
proliferated showed lower expression of CD86, CD80, CD40 and CD25. This might be 
because only the original B cell population was activated by CD40L on day 1, and the T cells 
in the co-culture system were less potent than CD40L-transfected L cells in further 
stimulating the newly proliferated B cells. In addition, IL-10 and TNF-α positive B cells 
were also lower in the proliferated population. These could partly explain the findings 
described above in which the activated B cells had significantly lower IL-10 and TNF-α than 
the un-activated B cells after 12 days (Figure 5.6.2F and G): the activated B cells 
demonstrated higher proliferation, with the proliferated cells having lower positivity for these 
two cytokines. In contrast, no significant difference was found in GM-CSF and IL-6 
positivity between the proliferated and un-proliferated population. Since activated B cells 
have significantly higher IL-6 positivity (Figure 5.6.2I), it could be argued that the CD40 
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ligation might have had a prolonged effect on B cell expression of IL-6, not only increasing 
the positivity of IL-6 among the original populations, but also among the proliferated cells.  
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Figure 5.8.1. Expression of CD86, CD80, CD40, CD25, GM-CSF, IL-6, IL-10 and TNF-α in proliferated 
and un-proliferated B cells after 1 day’s activation by CD40L-transfected L cells followed by 11 days’ co-
culture with CD4+ T cells. ***p<0.001, ****p<0.0001. 
To assess the immunological phenotype of the proliferated T cells I compared the positivity 
of intracellular cytokines IL-17, IL-10 and IFN-γ in the proliferated and un-proliferated CD4+ 
T cells (Figure 5.8.2). The production of IL-17 and IFN-γ were significantly increased in the 
proliferated cells (both p<0.0001), whereas the production of IL-10 was significantly 
decreased as compared with the un-proliferated cells (p=0.0002). These data imply that the 
activated B cells not only promoted naïve T cell proliferation, but also induced T cell 
differentiation towards Th1 and Th17 responses, indicating that in subjects carrying the risk 
allele at rs9282641, CD40 activated B cells are likely to result in a higher proliferation in 
naïve T cells, with the cells produced having more pro-inflammatory and less immune 
regulatory phenotype. 
 
Figure 5.8.2. Cytokine positivity in proliferated and un-proliferated CD4+ T cells’ after 11 days’ co-culture 
with CD40L-activated B cells. ***p<0.001, ****p<0.0001. 
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5.9 Comparison between MS and healthy subjects 
To compare and contrast these observed effects in the context of disease I went on to repeat 
the analysis described above in 9 MS patients. Given the low minor allele frequency of 
rs9282641 in the general population, it is unsurprising that none of the studied individuals 
was minor allele homozygotes (AA). However, as the rs9282641 SNP had been genotyped in 
many of the patients attending our local MS clinic, I was able to balance to some extent 
recruitment of AG and GG genotypes (see appendix for clinical details and current treatment 
for these subjects). As with samples from the CBR, I was blind to the genotype of study 
subjects until after all sample processing had been completed.  
In contrast to the results described in the previous chapter, MS patients showed lower 
positivity of the pro-inflammatory surface markers CD86, CD80 and CD25, and higher 
positivity of the immune regulatory CD40, and also showed lower positivity for the pro-
inflammatory GM-CSF, IL-6 and TNF-α but no statistically significant difference in IL-10 
positivity (see Figures 5.9.1 and 5.9.2). While these differences might be disease specific, it is 
also possible that they are a consequence of the immune-modulatory drugs being taken by 
these patients.  
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Figure 5.9.1. Surface marker and cytokine expression in B cells from treated MS patients and healthy 
controls. *p<0.05, ***p<0.001  
 
Figure 5.9.2. Cytokine expression in CD4+ T cells from treated MS patients and healthy controls.  
Comparing the proliferation of B cells and CD4+ T cells in treated MS patients and healthy 
controls revealed that in the activated condition B cells and T cells demonstrated higher 
proliferation in healthy controls (Figure 5.9.3). There was no statistically significant 
difference in the expression of surface and intracellular markers in B cells from MS patients 
and healthy controls (Figure 5.9.4). Similarly, B cells from treated MS patients demonstrated 
slightly lower CD86 positivity and higher CD40 positivity in both activated and un-activated 
conditions than B cells from healthy controls. The positivity of IL-17 and IL-10 was 
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considerably lower in MS samples in the three in vitro conditions (Figure 5.9.5). In addition, 
the difference of IL-10 positivity in the activated and un-activated conditions reached 
nominally significant level (P=0.04 and P=0.02 respectively). No statistically significant 
difference was found in T cells’ positivity of IFN-γ. 
 
Figure 5.9.3. Proliferation of B cells and CD4+ T cells from treated MS patients and healthy controls.  
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Figure 5.9.4. Surface marker and cytokine expression in B cells from treated MS patients and healthy 
controls after 12 days of co-culture, with and without pre-activation.  
 
Figure5.9.5. Expression of intracellular cytokine markers by CD4+ T cells from treated MS patients and 
healthy controls after 12 days of culture alone and co-culture, with and without pre-activated B cells.  
In short, the data from treated MS samples shows that the expression of surface markers and 
cytokines is similar to that seen in healthy controls, with the few differences observed which 
may be related to treatments being received by the subjects in the patient group. To confirm 
these differences as disease related, a large number of untreated patients would need to be 
studied in future experiments 
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5.10 Summaries and conclusions 
In this chapter, I have described how I established B cell and T cell panels to assess the 
phenotypes of naïve T cells and B cells. In line with the results from the previous chapter, 
memory B cells demonstrated significantly higher expression of surface and intracellular 
markers than naïve B cells. Preliminary experiments comparing alternate methods for 
isolating naïve T cells and B cells showed that the Influx Cell Sorter was the most suitable 
approach for this study. Since even minimal changes of lymphocyte gating could in principle 
influence the measurement of proliferation, the gating strategies were adjusted accordingly in 
order to minimize the potential bias, and stringent quality control measures were employed to 
exclude data of inadequate quality from analysis. 
In my B and T cell co-culture system, I found that stimulated B cells displayed significantly 
higher proliferation, CD80 and IL-6 expression, but lower IL-10 and TNF-α expression than 
unstimulated B cells. In accordance with this, T cells co-cultured with activated B cells 
showed significantly higher proliferation and expression of IFN-γ but lower IL-10 expression 
than T cells co-cultured with un-activated B cells or T cells cultured alone. These results 
confirmed the efficacy of the co-culturing of B cells and T cells I employed in this study. Of 
note, a distinct CD86 positive T cell population was found after 12 days’ co-culture. In 
contrast to B cells, which displayed significantly higher CD86 positivity when stimulated, T 
cells co-cultured with stimulated B cells demonstrated lower percentage of CD86+ cells than 
those cultured with unstimulated B cells. 
The genotypic effects on T cells were investigated using 14 pairs of homozygous healthy 
controls carrying either AA or GG genotypes at rs9282641. Despite the fact that the 
differences in CD86 expression on B cells were not statistically significant in this modest 
samples size, the T cells from GG individuals demonstrated significantly higher proliferation 
when cultured with the CD40L-activated B cells from the same individuals, with the 
proliferated cells producing higher level of IFN-γ and IL-17 but lower IL-10 level.  
Finally, in keeping with the results from previous chapters, I found that the samples from 
treated MS behaved very much like those from healthy controls under in vitro conditions. 
Although no statistical difference was found between the two groups, there was a trend of 
lower expression of pro-inflammatory CD86, CD80 and CD25, but higher CD40 expression 
in B cells from treated MS samples than health controls, in addition to a general decreased 
cytokine production by B cells and T cells. To confirm these trends, more MS samples from 
untreated patients would need to be included in future studies.  
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Chapter 6 Discussion 
6.1 Correlating phenotypes with gene expression 
In my research, I have shown that the genotype at rs9282641 influences the expression of 
CD86 in cultured lymphocytes. According to Gencode Release 21 (GRCh38), the CD86 gene 
contains eight exons and spans 65kb on chromosome 3q21. To date nine alternate transcripts 
have been described; the full-length transcript coding for the membrane bound protein CD86 
(also known as B7-2A). Among these different transcripts, five start with exon 1 and four 
with exon 2. Four transcripts lack the transmembrane domain encoded by exon 6 and are 
therefore soluble form of CD86 (sCD86). As well as the full-length transcript three alternate 
isoforms have been observed in humans, the two soluble isoforms, B7-2B and CD86ΔEC 
(Jeannin et al. 2000; Magistrelli et al. 2001), and one membrane bound form which lacks the 
IgV-like counter-receptor binding domain (B7-2C) (Kapsogeorgou et al. 2008). The 
proportion of the full length functional CD86 is relatively low in resting APCs, but increases 
upon activation, whereas the truncated isoforms, which are unable to provide co-stimulation 
for T cells, were found to behave in the opposite manner (Jeannin et al. 2000). It therefore 
follows that the efficacy of the interaction between CD86 and its cognate receptors on T cells 
is likely to be partially determined by the relative proportion of these isoforms 
(Kapsogeorgou et al. 2008). Unfortunately, the antibody I used to detect CD86 in my 
research does not distinguish between the different surface-bound isoforms, so it was not 
possible for me to explore the extent to which genotype influences the balance of alternate 
transcripts/isoforms. It remains possible that the effects of genotype I observed on cultured 
cells are primarily driven by altered balance in isoform production rather than changes in 
absolute surface expression of CD86, although clearly there are changes in this absolute 
surface expression. Since rs9282641 is located within the 5’UTR of exon 2 of CD86, it had 
been hypothesized that the genotype may alter the relative proportion of the alternate soluble 
forms of CD86 (Smets et al., 2018). However, in the ex vivo cells, they found no effect of 
rs9282641 genotype on the serum level of sCD86 or on the relative proportion of transcripts 
with different starting exons or transmembrane domains. I did not explore these issues in the 
activated cultures, so it remains possible that the rs9282641 genotype might influence these 
factors after activation.  
It has previously been shown that the soluble isoforms of CD40 (sCD40) produced by the 
transcripts lacking either exon 5 or exon 6 exert antagonistic effects on membranous CD40L 
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(Eshel et al., 2008), and that during activation stages there is a shift in pre-CD40 RNA 
splicing away from signal-transducible full length mRNA towards signal-nontransducible 
mRNAs, thereby reducing the functional form of CD40 available on the cell surface (Tone et 
al., 2001). In the context of these known negative feedback systems, it was unsurprising that 
the percentage of CD40+ B cells decreased significantly after 3 day’s activation with CD40L. 
The results showing that subjects carrying the MS risk allele (rs4810485*T) had even lower 
CD40 surface expression after activation implies that those individuals carrying this allele are 
more sensitive to this regulatory post-transcriptional splicing feedback mechanism, which is 
in line with earlier observations confirming that carrying the MS risk allele rs4810485*T 
increases the proportion of exon 5-lacking isoform and decreases the proportion of exon 6-
lacking isoform (Smets et al., 2018).  
In order to further explore the extent to which altered soluble isoform balance plays a role 
mediating the observed effects of MS risk alleles I collected and stored the 3-day and 12-day 
culture medium from the 136 healthy controls I studied. This material is available and could 
be quantified using the enzyme linked immunosorbent assay (ELISA) in the future. I was 
unable to undertake this additional work due to limited research budget.  
6.2 How B cells may influence T cell responses 
6.2.1 Implications from genetic studies 
A considerable proportion of the genes implicated by GWAS relate to intercellular signalling 
between APCs and T lymphocytes (Sawcer et al., 2014) and show a notable bias in favour of 
the ligands/receptors expressed on the APCs side of the interaction. For example, the MHC 
class II molecules show strong association, but no significant association has emerged in T 
cell receptor (TCR) gene regions (Sawcer et al., 2014). The GWAS undertaken by my 
supervisor identified three common variants that all lie close to the CD86 gene on 
chromosome 3q21 and independently influenced susceptibility to MS (Sawcer et al., 2011). 
Following up these discoveries my predecessor, Dr. Fiddes, showed that the carriage of the 
risk allele from one of these variants, rs9282641,increases the proportion of CD86+ naïve B 
cells in ex vivo condition, and therefore suggested that this variant might exerted its effect on 
MS risk by promoting the activation of T cells (Smets et al., 2018). It seemed likely that this 
effect would primarily be relevant in the context of immune stimulation and therefore 
interesting that variants close to CD40 were also associated with MS risk and influenced the 
expression of this B cell receptor. In my research, I wanted to test and explore these 
suggestions and reasoned that stimulation of CD40 would likely be a disease-relevant manner 
in which to activate the B cells. Using co-culture experiments, I have shown that the 
proliferation of T cells is indeed promoted by CD40L-activated B cells, and also that carrying 
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the risk allele at rs9282641 increases the resulting proliferation of T cells. A range of 
molecular mechanisms might underlie this genotype-dependent interplay between B cells and 
T cells. 
6.2.2 Roles played by B7 molecules 
In recently published work it was shown that the auto-proliferation of peripheral Th1 cells is 
enhanced in MS, and that the extent of this auto-proliferation is increased in individuals 
carrying the MS associated allele HLA-DR15 (Jelcic et al., 2018). These researchers co-
cultured T and B cells (both activated and un-activated) and, in line with my data, saw 
significantly higher proliferation of T cells in these co-cultures compared with when T cells 
auto-proliferated in lone cultures. In considering the role of the B7 molecules (CD86 and 
CD80) in these processes, it is important to remember that although interaction with the 
CD28 co-receptor has stimulatory effects, interaction with the alternative co-receptor CTLA-
4 (CD152), which is constitutively expressed by Tregs, has inhibitory effect (Wing et al., 
2014; Crotty, 2015). The impact of increased CD86 is thus dependent upon the context and 
partner cells encountered. 
The importance of B7 molecules in the interaction between APCs and T cells has been noted 
in both murine and human studies. In the EAE model, it was found that the conversion of 
effector T cells to Tregs relied on the interaction with CD80 and CD86 (Mann et al., 2007). 
In human studies, it has been reported in a case-control study that polymorphisms in 
CD28/CTLA-4–CD80/CD86 interaction could influence the risk of MS and the age of onset 
(Wagner et al., 2015). In line with this, an MRI study has shown that B cells from MS 
patients with high neurodegeneration had significantly higher expression of both CD86 and 
CD80 (Comebella et al., 2015). Conversely, Foxp3+CD4+ follicular regulatory T cells 
expressing CXCR5 and Bcl6 can down-regulate B cell expression of CD80 and CD86, 
thereby impeding the interactions between B cells and T cells (Wing and Sakaguchi, 2010).  
In accordance with the data presented by Jelcic et al., who found that T cell proliferation is 
primarily dependent on memory B cells, other researchers have shown that both class-
switched and non-class-switched memory B cells were able to elicit CD4+ T cell proliferative 
responses in vitro, whereas naïve B cells failed to induce T cell activation irrespective of the 
number of B cells cultured with T cells (Good et al., 2009). Since blocking CD86 and CD80 
would significantly reduce T cell proliferation, it was argued that the T cell responses were 
induced via the expression of CD86 and CD80 by B cells (Good et al., 2009). Therefore, 
observed differences in naïve and memory B cells’ capacity in inducing T cell responses 
observed by Jelcic et al. might simply relate to the low expression of CD86 and CD80 on the 
surface of ex vivo naïve B cells as compared with memory B cells (a situation which changes 
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after stimulation). Certainly, one of the most noteworthy phenotypic differences between 
naïve and memory B cells that I observed was the expression level of CD86 and CD80, with 
ex vivo memory B cells having significantly higher CD86 and CD80 positivity. This 
difference in the expression of these molecules by naïve and memory B cells might underlie 
the difference in T cell auto-proliferation seen by Jelcic et al. In keeping with earlier work 
(Bar-Or et al., 2001), I have shown that the expression of CD86 and CD80 on naïve cells 
increased to a level similar to that of resting state memory B cells when these cells were 
activated by CD40L. In the B/T cell co-culture experiments, T cells demonstrated 
significantly higher proliferation when co-cultured with activated B cells as compared with 
un-activated B cells, which had much lower CD86 and CD80 expression. It has been 
suggested that the dysregulated B cell signalling might be sufficient to induce the initial 
breaks in T cell tolerance and induce CD4+ T cell expansion and activation during 
autoimmunity (Jackson et al., 2015). Therefore, the T cell responses relevant to the 
pathogenesis of MS might be highly dependent on the co-stimulatory interaction with B cells. 
6.2.3 T cells’ expression of pro-/anti-inflammatory cytokines 
As well as showing that co-culturing CD4+ T cells with autologous B cells increases their 
proliferation, I have also shown that the cells generated in this way have higher positivity for 
pro-inflammatory cytokines such as IFN-γ and IL-17, and lower positivity for anti-
inflammatory cytokines such as IL-10 (see Figures 5.6.3 and 5.8.2). The increase of these 
pro-inflammatory cytokines is likely to be disease relevant, given the correlation of IFN-γ 
with disability in MS (Moldovan et al., 2003), the adverse effects of exogenous IFN-γ 
(Panitch et al., 1987) and the likely role of IL-17-secreting CD4 T cells (Th17 cells) and γδ T 
cells in the pathogenesis of MS (Gold and Luher, 2008; McGinley at al., 2018). Although 
how these cytokines initiate and augment the disease remains incompletely understood, these 
studies strongly implicate IFN-γ and IL-17-secreting CD4 T cells as pathogenic drivers of 
MS. 
Although the suppressive effects of Forkhead box protein 3 (FoxP3) expressing regulatory T 
(Treg) cells are primarily mediated via cell-contact mechanisms (Tao et al., 2017), it has 
recently been recognized that the so-called type 1 regulatory T (Tr1) exert many of their 
effects via their secretion of IL-10 (Gregori et al., 2012). Inadequacy in the production of this 
potent anti-inflammatory cytokine is believed to play a crucial role in the development of 
many autoimmune diseases (Iyer and Cheng, 2012). It is also been shown that the FoxP3- 
effector T cells can acquire the capacity of producing IL-10 (Korn and Kallies, 2017). In 
keeping with these data, a recent high-throughput transcription analysis has shown that IL-10 
expression is suppressed in MS and negatively correlated with disease activity (Hu et al., 
2017).  
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In my research I have thus been able to confirm that the genotype dependent increase in 
CD86 expression on B cells observed by Dr Fiddes in his PhD do indeed correlate with 
increased proliferation and pro-inflammatory differentiation of T cells; a process which could 
be a therapeutic target in MS. However, its notable that the clinical experience with the 
CTLA4-Ig fusion protein Abatacept, which blocks the CD28-B7 costimulatory pathway was 
disappointing; the clinical trial, A Cooperative Clinical Study of Abatacept in Multiple 
Sclerosis, (ACCLAIM) (Khoury et al., 2017) being negative despite the drug being approved 
for the treatment of RA and juvenile idiopathic arthritis. The possible explanations behind 
this failure are worthy of further consideration. 
6.3 CD86 and the failure of Abatacept in MS 
6.3.1 Unspecific target cell types 
Given that CD86 and CD80 can result in anti-inflammatory as well as pro-inflammatory 
signalling, it is possible that the lack of any cell type specificity in the blockade of co-
stimulatory signalling resulting from Abatacept might have little overall effect, with its 
wanted blockade of pro-inflammatory effects being balanced (or even outweighed) by its 
blockade of anti-inflammatory effects on other cell types. It is clear that cellular subtypes 
differ in their expression of co-stimulatory surface (Pieper et al., 2013).  
In my research I confirmed that CD86 is not restricted to B cells but is also found on T cells 
(see Figure 5.6.4A), indicating that Abatacept might as well have effects on signalling 
coming from both of these cell types (and in principle any other cell type expressing CD86). 
Although the exact function of CD86 on T cells remains unclear, it has been suggested that 
CD86+ T cells can also serve as APCs, enabling sustained T cell proliferation (Lal et al., 
1996; Menezes et al., 2014). In line with this, another human study has shown that CD86+ 
memory effector T cells can enhance naïve T cells proliferation and their production of IFN-γ 
(Jeannin et al., 1999).  Since the consequences of blocking B7 costimulatory signalling in T 
cells is unknown, this again might offset the anticipated anti-inflammatory functions of 
Abatacept. Aggravation of disease activity induced by blocking B7 medicated signalling has 
been reported by others (Kuchroo et al., 1995; Menezes et al., 2014), so perhaps the negative 
results of the Abatacept trial were not so unexpected.  
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6.3.2 Roles played by CD80 
The fact that Abatacept blocks CD80 as well as CD86 could be another source of unwanted 
and unexpected effect that offset the benefits anticipated in the Abatacept trial. Despite their 
mostly overlapping roles as co-stimulatory molecules, CD86 and CD80 also have some 
unique modulatory roles. For example, although the ligation of CD86 and CD80 with CD28 
leads to shared early signalling transduction events, it has been suggested that they induce 
distinct signalling pathways, and that the tyrosine phosphorylation of CD28 initiated by these 
ligands is quantitatively different (Slavik et al., 1999). In line with this, different outcomes 
have been observed when blocking either CD86 or CD80 using antibodies with greater 
specificity.  In a mouse transplantation study, researchers found that silencing CD86 in 
dendritic cells via siRNA transfection significantly reduced the IL-2 and IFN-γ production 
while increasing the production of IL-10 and TGF-β, thereby inducing immune tolerance, 
whereas silencing CD80 in the same manner had no such effects (Ke et al., 2016). It has also 
been found in a virus infection model that the expression of CD86, but not CD80, by B cells 
is crucial to the formation of follicular T helper cells, which are involved in germinal centre 
development (Salek-Ardakani et al., 2011). By contrast, in acute viral myocarditis models, 
treating the mice with anti-CD80 monoclonal antibodies, but not anti-CD86 antibodies, will 
markedly suppress ROR-γt mRNA expression and Th17 cell differentiation (Huang et al., 
2018). These data confirm that the effects of CD86 and CD80 on T cells are not identical or 
redundant.  
In addition to their distinct effects on T cells, the dynamic regulation of their expression also 
differs. It has been suggested that CD86 has a dominant role during the initiation of immune 
reactions, whereas CD80 plays a more prominent role in chronic inflammatory conditions 
(Sharpe and Freeman, 2002). This is perhaps due to the fact that upon B cell activation, CD86 
levels typically increase more rapidly and to a higher level than CD80 (Bar-Or et al., 2001). 
In agreement with these findings, I saw notable differences in the time course of CD86 and 
CD80 expression during my cultures, with increased expression of CD86 occurring much 
earlier than increased expression of CD80.  It has been found that inhibiting the expression of 
Dicer, which is involved in the biogenesis of microRNAs, leads to increased expression of 
CD80, but not CD86 (Aung and Balashov, 2015).  
6.4 CD40 and its complex roles in B cell activation 
My predecessor Dr Fiddes showed that in resting cells the MS associated variants rs9282641 
and rs4810485 exert their strongest respective effects on the expression of CD86 and CD40 
in naïve B cells. These data therefore suggest that this cellular subtype is perhaps the most 
implicated cell type in MS, and also that activation via CD40 might be the most disease-
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relevant mechanism for stimulating B cells. In keeping with these results, the expression of 
CD86 has previously been shown to be increased in B cells in the context of MS (Bar-Or et 
al., 2001), again with the greatest increase being seen in naïve B cells when activated in vitro 
(Kinnunen et al., 2013). In my research I wanted to determine the effects of these genotypes 
in the context of stimulation and optimized an experimental design that activated B cells via 
CD40, a critical co-stimulatory molecule in APCs and innate immune cells (Elgueta et al., 
2009).  
Engagement of CD40 with CD40L promotes both canonical and non-canonical NF-kB 
pathways in B cells, which are required for germinal centre (GC) formation, immunoglobulin 
(Ig) class-switching and affinity maturation, as well as memory B cells and plasma cells 
differentiation (Mauri et al., 2003, Lemoine et al., 2011, Hostager and Bishop, 2013). The 
importance of CD40 in immune regulation is also suggested by the association of rs4810485 
with a range of autoimmune diseases in addition to MS, including RA (Raychaudhuri et al., 
2008), Graves’ disease (GD) (Tomer et al., 2002; Li et al., 2012), SLE (Vazgiourakis et al., 
2011), Crohn’s disease (Blanco-Kelly et al., 2010; Jostins et al., 2012) and Kawasaki disease 
(Onouchi et al., 2012). As with many other overlapping GWAS risk variants, the effects of 
the MS risk allele (T) (Sawcer et al., 2011; Beecham et al., 2013) vary between diseases, with 
the T allele increasing risk of inflammatory bowel disease (IBD) (Jostins et al., 2012), but 
reducing the risk of GD (Tomer et al., 2002), SLE (Vazgiourakis et al., 2011), RA 
(Raychaudhuri et al., 2008) and Kawasaki disease (Onouchi et al., 2012). These differences 
presumably reflect varying importance of the complex and pleiotropic effects of CD40 
signalling. For example, the risk allele for GD (Jacobson et al., 2005) at rs1883832 (a perfect 
proxy for rs4810485) is associated with increased CD40 expression (C, major allele), 
whereas the same risk allele for MS is associated with decreased expression of CD40 (T, 
minor allele) (Gandhi et al., 2010; Field et al., 2015).  
It has been reported that dual stimulation (sequential BCR engagement followed by CD40 
signalling) results in lower production of IL-10 and higher production of TNF-α, than CD40 
signalling alone (Duddy et al., 2007), and also that activated T cells can act as a major source 
CD40L stimulation to B cells (Vazquez et al., 2015).  Furthermore, in the context of disease it 
has been observed that B cells can respond differently to CD40 activation. For example, 
transitional B cells isolated from SLE patients have been found to be refractory to CD40 
stimulation (Blair et al., 2010). It should also be noted that although CD40L has been 
suggested as the primary stimuli for B cell activation, other co-stimulatory signals provided 
by activated CD4+ T cells might also play a part in the development of regulatory B cells 
(Mauri et al., 2008; Mauri, 2010).  
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Since activating B cells with CD40L-transfected L cells can significantly increase the 
expression of CD86 and CD80 (Nova-Lamperti et al., 2016), intuitively, it might be expected 
that genetic variants reducing CD40 expression would be associated with reduced MS risk. In 
fact, the reverse is seen, with variants reducing the level of CD40 resulting in increased risk 
of MS (Sawcer et al., 2011). In addition, no association between the CD40 SNP and the 
expression of CD86 and CD80 was found in the samples that I have processed. It is clear 
therefore that the reduced expression of CD40 resulting from carrying the risk allele (T) at 
rs4810485 must have more effects that just reducing CD86 and CD80 expression (effects 
which would be expected to reduce rather than increase MS risk). In keeping with these 
GWAS findings, it has been noted that blocking the CD40-CD40L pathway has beneficial 
effects in EAE models (Howard et al., 1999), although the effects of such blocking in humans 
are less clear. Intriguingly, it has been shown that at the mRNA level the expression of CD40 
is higher in MS patients than in healthy controls, which is contrary to the decreased CD40 
positivity on cell surface seen in individuals at higher risk (Huang et al., 2000). As noted 
previously, such inconsistency between RNA and protein expression might be due to 
alterations in the balance of CD40 isoforms: an increased transcription of the truncated CD40 
mRNA and simultaneous decrease of cell surface CD40 protein in MS patients as compared 
to healthy individuals. 
6.5 From B cell subtypes to single cell transcriptional analysis 
As mentioned in Chapter 1, the notion of MS being an autoimmune disease driven solely by 
myelin-reactive T cells has been challenged by recent progress in the understanding of B 
cells. It is now well recognized that B cells are able to function as professional APCs, and 
indeed are much more potent in this role than dendritic cells and macrophages, especially 
when the concentration of antigens is low (Rahmanzadeh et al., 2018). It is also clear that B 
cells can polarize the differentiation of T cell towards Th1, Th2 or Th17 via their production 
of a wide spectrum of cytokines (Jackson et al., 2015). B cell depleting therapy (BCDT) that 
targets CD20 has emerged as a highly effective treatment for controlling inflammatory 
activity in various autoimmune diseases, including MS (Franciotta et al., 2008). Contrary to 
CD19, which is expressed on all circulating B cell lineage and regulates the signalling 
threshold for B cell activation, CD20 is only expressed by B cells from the pre-B cell stage 
till the mature naive and memory B cell stage, and its precise function remains unknown 
(Baecher-Allan et al., 2018). Therefore, the depletion of CD20+ B cells targets naïve and 
memory B cells while sparing antibody producing plasma cells. So far, three anti-CD20 
antibodies targeting different CD20 epitopes have been approved or are under investigation in 
clinical trials for MS, namely rituximab (chimeric human/mouse Ig G1), ocrelizumab 
(humanized Ig G1), and ofatumumab (full-length human Ig G1) (Rahmanzadeh et al., 2018).  
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It is possible that the anti-CD20 drugs could result in long term disease regulation benefits in 
MS perhaps by reducing pro-inflammatory memory B cells, and/or restoring regulatory B cell 
populations in circulation. However, in some cases B cell deficiency or B cell depletion 
therapies have been shown to paradoxically exacerbate rather than ameliorate the 
inflammatory condition (Dass et al., 2007; Goetz et al., 2007). For example, the recombinant 
fusion protein atacicept, which was designed to block B cell activities via the BLyS/April 
receptor, has turned out to worsen CNS inflammation in a phase II clinical trial of MS 
(Kappos et al., 2014). Such paradoxical outcomes might be due in part to the heterogeneity of 
B cells, which could be further divided into various cellular subtypes having completely 
different phenotypes and cytokine secretion profile. Thus, it could be postulated that the 
pathogenesis of MS might result from the dysfunction of a relatively small subset of B cells, 
within which we might expect more prominent effects of MS associated risk alleles.  
Cell type specific differences have been reported in studies comparing MS patients with 
healthy controls (Niino et al., 2009), and those comparing patients in the relapse and 
remission phases of the disease (Fraussen et al., 2016). It is worth noting that most existing 
disease-modifying therapies for MS modulate B cell immunity to some extent (Longbrake et 
al., 2016). In general, these therapies lead to a relative decrease of memory B cells and a 
concomitant expansion of immature and naïve B cells, which can further increase the 
production of IL-10 and concurrently suppress the secretion of pro-inflammatory cytokines 
(Fillatreau et al., 2002; Mauri et al, 2003; Claes et al., 2014; Matsumoto et al., 2015). 
Moreover, the auto-proliferation of CD4 T cells was found to be positively associated with 
memory B cells and negatively with naïve B cells (Jelcic et al., 2018), so it is possible that 
not all of the changes in B cells induced by existing therapies are helpful. Given the 
overwhelming evidence supporting cellular subtype specific effects, including the work of 
my predecessor Dr Fiddes, it was clear that in my research I needs to explore the effects of 
genotype in a cell type specific manner, following this logic to its conclusion it would seem 
logical to infer that ultimately single cell resolution analysis would likely be optimal. 
Unfortunately, although this is now possible, the techniques currently available are 
prohibitively expensive. 
I used several surface markers to characterize the B cell types and assess activation. In line 
with existing literature (Amu et al., 2007), I found that in ex vivo cells CD25 positivity was 
significantly higher in memory B cells than in naïve B cells. However, after 12 days’ culture, 
there was no statistically significant evidence for association of CD25 positivity with 
rs9282641 in any of the B cells subtypes. Given the pivotal roles of IL-10 secreting 
regulatory B cells (Breg) in murine models of autoimmune diseases, I was keen to also assess 
these cells in humans. However, as there are currently no transcription factors or surface 
markers that can robustly define these cells, it was only possible to explore the impact of 
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genotype on these cells indirectly, via the production of IL-10 (Sims et al., 2005). It has 
previously been observed that the regulatory capacity of CD19+CD24hiCD38hi transitional B 
cells was impaired in patients affected by autoimmune diseases (Blair et al., 2010; Lemoine 
et al., 2011; Oka et al., 2014). Unfortunately, primarily due to the small numbers of 
transitional B cells available after culturing, I was unable to reliably assess IL-10 expression 
in this subtype in my experiments. The low number is unsurprising given the short half-life of 
the transitional B cells (Vitale et al., 2010; Bemark, 2015). Assessment of IL-10 in 
plasmablasts was similarly limited by low cell number. In addition, I found no evidence to 
suggest that any of the three SNPs I investigated influence the composition of B cells under 
any of the study conditions in my analysis, although it is well established that other genetic 
variants alter the relative proportion of immune cells (Orru et al., 2013; Astel et al., 2016; 
Lagou et al., 2018).  
Given that the function of B cell is reflected by its cytokine profile as well as its surface 
markers (Li et al., 2016), I included assessment of TNF-α, IL-10, IL-6 and GM-CSF in my 
flow panels. Others have found evidence suggesting that dysregulated B cell cytokine 
production plays a crucial part in MS (Vazquez et al., 2015), in particular that a deficiency in 
the production of anti-inflammatory IL-10 by B cells is associated with a more aggressive 
disease course (Duddy et al., 2007; Bar et al., 2012; Li et al., 2015). The regulatory capacity 
of B cells has been recognized in both murine autoimmunity models and human clinical trials 
(Berthelot et al., 2012). It has been reported that in the EAE model transplanting IL-10-
producing B cells into B cell deficient mice reduces the production of pro-inflammatory 
cytokines and the proliferation of auto-reactive CD4+ T cell, and that transplanting B cells 
that are CD40 deficient cannot restore the balance of immunity (Yoshizaki et al., 2012). In 
keeping with this suggestion that IL-10 production might be dependent on CD40 signalling, I 
have found that activated B cells had significantly lower CD40 positivity at day 3 and lower 
IL-10 positivity at day 12. In our previously published work, we found nominally significant 
association between IL-10 levels and the MS risk allele rs4810485*T (Smets el al., 2018). 
Despite these data suggesting the importance of cytokine production in B cell function, I 
found no statistically significant evidence for association of these intracellular makers with 
any of the three key variants I tested. 
In terms of T cell responses, it has been suggested that IL-10 secreted by transitional B cells 
can prevent the production of pro-inflammatory cytokines by CD4+ T cells (Blair et al., 2010; 
Lemoine et al., 2011), and that transitional B cells produce higher levels of IL-10 as 
compared to other B cell subtypes after CD40 engagement (Nova-Lamperti et al., 2016). 
Transitional B cells can also inhibit the differentiation of naïve T cells into Th17 and 
suppress their secretion of TNF-α and IFN-γ, in addition to promoting their conversion into 
Tregs (Flores-Borja et al., 2013; Wang et al., 2015). It has therefore been hypothesized that 
regulatory B cells, which might be a heterogeneous population of cells at various stages of 
differentiation, act at early stages to facilitate Tregs recruitment and become less active once 
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Tregs function become optimal (Berthelot et al., 2012). However, using the functional 
definition to characterize the population of regulatory B cells makes it difficult to determine 
whether the genotype/disease associated differences in their activity are the results of 
numerical or functional defects of this population, and whether such suppressive functions 
are fixed or only transient (Baecher-Alan et al., 2018).  
Although our knowledge of human B cell development has improved considerably during the 
past two decades, most of our understanding of B cell differentiation is based on the presence 
or absence of certain cellular markers, and unavoidably, a great deal of cellular diversity 
involved is often underappreciated (Bemark, 2015). For instance, to separate naïve B cells 
from total B cells, the most straightforward way is to remove cells that are CD27 positive. 
However, such an approach would not differentiate naïve B cells from the cells staying at the 
transitional stages, which have been suggested to be associated with potential 
immunosuppressive role (Li et al., 2015). Moreover, it has also been demonstrated that 
substantial numbers of class-switched memory B cells do not express CD27 (Fecteau et al., 
2006). Therefore, the cells gated within the naïve group could be a mixture of immature B 
cells at various developmental stages. For these reasons, it needs to be remembered that the B 
cell subtypes defined using flow cytometry are likely to be heterogeneous rather than 
inevitably functionally or phenotypically identical. Focusing on cell populations broadly 
defined by surface markers unavoidably averages out such heterogeneity within those 
specific cellular subtypes.  
Although flow cytometry is one of the most frequently used methods of characterizing 
immune cells it is only able to measure a relatively few selected cell properties at any one 
time. This limitation means that the method can often only provide a crude guide to the 
functional nature of the analysed cells and inevitably misses much of the heterogeneity within 
those defined cellular subtypes. Given that cells are the most fundamental units of the 
immune system, the establishment of the whole gene expression profile within individual 
cells has the potential to overcome these limitations.  
6.6 Where next: Single cell expression profiling 
Ultimately, the behaviour of a cell is determined by the pattern of protein expression within 
the cell, which has been suggested to be primarily determined by transcription rather than 
translation or protein degradation (Battle et al., 2015). In turn, gene expression is determined 
by the particular set of transcription factors and cis-regulatory elements that are active in the 
cell (Ostuni et al., 2013). Genetic factors profoundly influence expression and many of the 
variants identified in GWAS lie in regulatory regions of the genome and likely exert their 
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effects by altering gene expression. However, deciphering the biological consequences of 
these noncoding variants has turned out to be extremely challenging (Farh et al., 2015). 
Given that the regulatory effects of genetic variation are frequently cell type and activation 
state specific, it is to be expected that identifying the disease relevant effects of the variants 
suggested by GWAS will require the analysis of expression in the relevant cell types under 
appropriate conditions. As CD86 and CD40 are expressed on B cells and are involved in 
immune signalling, it seemed logical to extend the work conducted by my predecessor and 
look at the expression of these receptors on B cells in the context of relevant stimulation. 
Although the number of regulatory elements in the human genome is enormous, the 
functional clusters of transcriptional enhancers, which drive the expression of genes that 
define the identity of the given cells, are more limited in number, and those variants 
associated with diseases are particularly enriched in these super-enhancers, especially in the 
cell types relevant to the diseases (Hnisz et al., 2013). However, identifying cell type specific 
eQTLs can be challenging when the cells of interest only makes up a small fraction of those 
tested (Wills et al., 2013). In contrast, single cell analysis has the potential to characters each 
cell individually, rather than considering the average properties of a group of cells defined in 
terms of a restricted number of canonically used surface makers.  
Next generation sequencing (NGS) technologies have enabled the efficient and robust 
characterization of the transcriptome at the single cell level in thousands of cells and have 
thereby enabled the detailed analysis of extremely rare cell types (Wu et al., 2017). Thus, 
exploring the effects of MS associated expression in cell types such as transitional B cells and 
plasmablasts would likely have been possible using this approach rather than FAC sorting. 
Furthermore, through single cell expression analysis it would be possible to group together 
cells with similar functional activity (as reflected by their gene expression profile) rather than 
on the basis of pre-determined surface markers, and thereby potentially identify previously 
un-recognised sub-types of immune cells.  
In NGS experiments, the most basic measurement unit is the read, which represents a 
fragment of cDNA being reverse transcribed and amplified (Wu et al., 2017). For single-cell 
RNA sequencing using mammalian cells, it has been recommended that 1 to 2 million reads 
per cell should be performed for capturing genes with confidence (Grün et al., 2014). As a 
consequence, these methods are currently primarily limited by their considerable 
computational and financial costs. These costs could be reduced by pre-sorting cells in those 
of interest (Drissen et al., 2016), but this inevitably limits the potential for the discovery of 
novel cell types. The approach is extremely sensitive and great care has to be taken to limit 
the impact of experimental variations and batch effects (Munro et al., 2014).  
If I had had the time and financial means to extend my research, I would have undertaken a 
single cell expression analysis in both MS patients and controls, with the control samples 
错误!使用“开始”选项卡将 Heading 2 应用于要在此处显示的文字。 错误!
使用“开始”选项卡将 Heading 2 应用于要在此处显示的文字。 
109 
 
selected so as to ensure a balance of genotype at the CD86 and CD40 SNPs. I would have 
used FACS to focus the sequencing efforts on to B cells but would have allowed the observed 
expression patterns to characterize the B cell sub-types. Variation in technical performance 
and low efficiency in the conversion from mRNA to cDNA are major problems with existing 
single cell transcription methods.  The use of exogenous RNA molecules as spike-in positive 
controls, such as the synthetic transcripts External RNA Controls Consortium RNA standards 
that have known sequence and abundance, can help to reduce the impact of such 
experimental variation (Munro et al., 2014), as can the incorporation of random barcode 
sequence of nucleotides, which function as unique molecular identifier (UMI) that effectively 
allows the counting of mRNA molecules (Islam et al., 2014). I anticipate that the resulting 
high-resolution single cell RNA-sequencing data set would greatly refine our understanding 
on the effects of MS associated variation in MS and might even identify previously un-
appreciated B cell sub-types.  
6.7 Limitations of this study 
There are several limitations inherent in the research I completed during my PhD. Firstly, like 
most other human based MS studies, I obtained my study samples from venous blood rather 
than from the brain itself or its draining lymphoid tissue. Given that the immunological 
phenotypes of cells in the periphery may not genuinely reflect the conditions behind the 
blood-brain barrier, it is possible that important effects relevant within the CNS might not be 
apparent in studies based on circulating immune cells. Cells acquired from CSF might have 
more closely represented those in the CNS, but it was infeasible to access large numbers of 
CSF samples from a cohort of healthy volunteers for ethical and practical reasons. Another 
limitation of my research is that although I have confirmed that the MS associated genotypes 
are associated with the surface expression level of CD86 and CD40 on B cells and that these 
changes result in increased proliferation of T cells, I have not established the underlying 
mechanisms by which these changes occur. The extensive LD associated with each of the 
associated SNPs means that the causal variants underlying these association have yet to be 
identified. If these associations could be fine-mapped, then genomic editing techniques could 
be employed to explore these mechanisms. Moreover, although there is compelling logic 
behind my use of CD40L-transfected L cells as the means to stimulate B cells, this is only 
one of many physiologically relevant modes of stimulation, and these alternatives remain 
unexplored. Finally, my work has focused on B cells and has not considered alternative APCs 
such as dendritic cells and macrophage (Korn and Kallies, 2017). Similarly, although CD4 T 
cells are considered the primary pathogenic drivers of MS, CD8 T cells might also play a role 
but were not specifically assessed in my cultures. In a recently published study of brain 
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infiltrating lymphocytes, the predominant cells identified were CD8+ T cells and CD20+ B 
cells irrespective of MS disease course or lesion stages, whereas CD4+ T cells were scarce 
(Machado-Santos et al., 2018). Expanding the work to include analysis of all potentially 
relevant cell types would be a logical extension to my research. 
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Concluding remarks 
In conclusion, in my PhD studies I assessed the influence of MS associated genotypes on B 
cells and T cells in both healthy volunteers and MS patients. My analysis confirmed that the 
MS risk alleles at rs9282641 and rs4810485 respectively lead to higher expression of CD86 
and lower expression of CD40 in the context of stimulation. Moreover, I was able to show 
that the expression changes induced by carrying the risk allele at rs9282641 result in 
increased proliferation of pro-inflammatory T cells. Overall, the results of my PhD studies 
have improved our understanding of the relationship between genotype and the development 
of MS and understanding that has the potential to promote the development of novel 
therapeutic strategies.  
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Appendix 
Treatment information of the recruited MS patients 
Date of collection Patient ID Treatment currently undertaken  
2017/3/17 C00TU0081a1v2 Fingolimod  
2016/7/8 C00TU0125a1v1 no treatment 
 
C00TU0126a1v1 no treatment 
 
C00TU0127a1v1 no treatment 
2016/7/22 C00TU0128a1v1 Avonex 
2016/7/29 C00TU0129a1v1 Avonex 
 
C00TU0130a1v1 Alemtuzumab  
2016/8/5 C00TU0131a1v1 no treatment 
 
C00TU0132a1v1 no treatment 
2016/10/28 C00TU0133a1v1 no treatment 
2016/8/12 C00TU0134a1v1 no treatment 
 
C00TU0135a1v1 no treatment 
 
C00TU0136a1v1 Rebif 
2016/9/30 C00TU0144a1v1 Tecfidera  
 
C00TU0145a1v1 Tecfidera  
2017/3/10 C00TU0146a1v1 first infusion of Tysabri 10/03/17  
 
C00TU0148a1v1 no treatment 
 
C00TU0149a1v1 No treatment (Avonex stopped in 2016) 
2017/5/19 C00TU0156a1v1 no treatment 
2018/8/3 C00TU0167a1v1 Copaxone   
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2017/11/10 C00TU0183a1v1 Rebif 
 
C00TU0191a1v1 Tecfidera  
2018/1/12 C00TU0226a1v1 Tysabri 
2018/1/19 C00TU0236a1v1 no treatment 
 
C00TU0273a1v1 Rebif 
2016/7/6 C00TU0504a1v1 no treatment 
2018/7/27 C00TU0903a1v2 no treatment 
2017/10/20 C00TU0905a1v1 Tecfidera  
 
C00TU09244a1v1 no treatment 
 
 
